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ABSTRACT
Conventionally, product development and manufacturing of 
pharmaceuticals are based on small molecules and simple chemical 
processes. Then at the end of the genomic era, the industry was 
forced to adopt sophisticated biotech-based approaches for 
innovation of new kinds of pharmaceutical products, termed 
biopharmaceuticals. Following the industrial transformation, 
anti-cancer therapy, therapeutic proteins, vaccines and hormone 
therapy become the major outputs. Specific biopharmaceutical 
products include insulin for diabetes, erythropoietin (EPO) to treat 
neutropenia, granulocytes-colony stimulating factors (G-CSFs), 
growth hormones, and cytokines (for therapeutic purposes). 
Currently, monoclonal antibodies (mAbs) are the fastest growing 
therapeutic proteins in R&D and market globally; targeting at cancer 
treatment, inflammatory and immune related diseases. Existing 
cytotoxic drugs have been rejuvenated via conjugation technology 
with MAbs to improve effects of the former. Lead by mAbs, 
therapeutic protein market has claimed at least 30% of the total value 
of biopharmaceuticals in the global market. Cytokines is already in 
advanced development for treatments of cancers, benign prostatic 
hyperplasia, gout and inflammatory conditions. Interestingly, insulin 
has been in the market for a long time, but R&D efforts are still 
strong especially on new formulation and delivery of oral or other 
non-invasive dosage. On the other hand, even though many vaccines 
are already well established in the market, new technologies are still 
needed to make those vaccines become more potent, cost effective 
and convenient. Previously, it was almost impossible to accelerate 
development of vaccines against some diseases as it was limited by 
technology. Currently, there are many new vaccines against existing 
targets and vaccines against new targets in the pipeline. Despite 
numbers of failures in the past, many biopharmaceutical companies 
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are not discouraged to develop difficult vaccines against major 
problems or complex diseases including malaria, dengue, hepatitis 
C and HIV. Acute issues on diseases, for instance bio-terrorism, 
SARS and influenza, became a major growth driver for development 
of new vaccines and method of production. The cost of producing 
biopharmaceuticals is nowhere going to be cheap. The advancement 
of biopharmaceutical industry also stimulates “fringe industries” 
that supports the entire value chain, for example an improved 
bio-process technology, chromatography, bio-assay development, 
preclinical and clinical trials contract research organisation (CRO), 
sophisticated manufacturing technology, bioinformatics, contract 
manufacturing organisation (CMO), cold-chain management and 
logistics. From the business perspective, the requirement for highly 
specialised knowledge and skilled worker, great amount of funding 
required for investment and long-term investment horizon with a 
big loop in J-Curve serve as great barriers to new entrants. Despite 
the high risks, many sophisticated investors treated this as a great 
opportunity for potential higher returns from successful investee 
companies, provided that they are well equipped with the necessary 
bullets for evaluation, forecasting and making the right decision 
before joining the party.  
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INTRODUCTION
The information needed to synthesize proteins, enzymes and ensure 
‘normal’ working of the body is coded by the genome. The genome 
is the complete genetic make-up of an individual and, in human, 
it is made of double helical strands of DNA. Specific sequences/
arrangements of the DNA, known as genes, contain information 
for synthesizing all the proteins and enzymes present in the body. 
The DNA strand consists of a chain of interlinked nucleotides, 
which are made of deoxyribose (a sugar) a phosphate group and an 
organic base, and hence the name deoxyribonucleic acid. Only four 
different bases - adenine (A), thymine (T), cytosine (C) and guanine 
(G) – are present in human/animal body. The base is attached to the 
sugar of a sugar-phosphate-sugar-phosphate structure and forms 
a strand. Complementary pairing of A-T and G-C of adjacent 
strands by hydrogen bonding results in the double helical DNA, 
similar to a twisted ladder. Aberrations in the sequence due to 
deletions, insertions, rearrangements and mutations are responsible 
for causing diseases. With the completion of Human Genome 
Project, 99.9% of the gene rich portion of the human genome has 
been sequenced. Currently, genomes of several animals, plant and 
microbes have been sequenced and, now, it could be accomplished 
at an affordable cost. In Malaysia, there are at least two government 
research institutions and one public listed company have acquired 
the capability to complement the genome sequencing services to 
the public. 
Protein synthesis begins with unwinding of the DNA double 
helix. The free strand of DNA then binds to ‘free’ bases present 
within the nucleus. The complementary strand created is known 
as messenger RNA (mRNA), and this process is known as 
transcription. During transcription, non-coding regions and other 
exons are removed. The transcribed mRNA enters the cytoplasm 
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and attaches to ribosomes. Each triplet of bases on the mRNA is 
known as a codon and codes for a specific amino acid. Triplets 
of bases on the transfer RNAs (tRNA) that are complementary 
to codons are known as anti-codons. Each anticodon binds to a 
particular amino acid present in the cytoplasm. The anti-codons 
on tRNA along with amino acids attach to complementary codons 
on mRNA and this process is known as translation. The sequential 
arrangement of amino acids as anti-codons bind to codons results 
in synthesis of proteins, by adding amino acids one by one akin to 
adding beads on a string.
A variation in the sequence of bases, termed as single nucleotide 
polymorphisms (SNPs), might be responsible for diseases. The 
altered sequence could code for defective proteins or enzymes, 
leading to disease manifestation. The most common variation is a 
single base substitution, known as single nucleotide polymorphism. 
Other serious defects are caused by mutations, which could range 
from deletion of a segment to translocation of chromosomal material 
to genetic inversions. Matters only worsened with multigenetic 
diseases such as cancer, diabetes, and heart disease, as no one 
had a clue as to what genes or interactions of sets of genes were 
responsible for these ailments. Improvement in sequencing 
technology raised hopes that answers might be just around the 
corner. The identity of defective region in our genome could give 
an insight into the disease pathogenesis and could also help identify 
novel drug targets. 
Drug discovery and development has been likened to trial-and-
error, involving screening for drug candidates amongst millions of 
compounds. It has been estimated that for every 5,000 potential 
candidates initially identified, 5 will enter clinical trials and 
ultimately one will be approved. The cost of developing one drug is 
staggering and now estimated to be RM2.5billion (USD800million) 
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instead RM1.6billion (USD500m) 10 years ago, with 42% being 
spent on preclinical studies and the remainder on clinical studies. 
Of all the drugs that are ultimately launched, about 10% of them 
face withdrawal due to some serious adverse reactions in patients. 
Avoiding these kinds of fiascos, either in late stage clinical trials 
or post-launch, could result in huge savings for the companies 
involved. Another source of savings to drug developers could come 
from reducing preclinical drug candidates to a more manageable 
level. In order to realise this, ones must understand the underlying 
genetic factors of the disease target. This approach suggests a 
departure from the trial-and-error approach to a more systematic 
approach where defined genetic areas will be targeted. Then, number 
of available genetic targets will determine the number of candidate 
drugs entering preclinical studies. As the number of candidate drugs 
entering the pipeline reduced, apart from increased productivity, 
investors and biopharmaceutical R&D companies will benefit from 
a cost perspective. An example of the kind of impact that genomic 
studies could have is the change of label for Pfizer’s Irinotecan in 
2005. Approved in 1996, Irinotecan is used to treat lung and colon 
cancers. In another example, dentification of the Her2 gene leads 
to the development of Herceptin. About 20% of breast cancer 
patients are classified as Her2 subtype, and Herceptin caused a 
33% increase in longevity in such patients. Similarly, 10% of lung 
cancer patients have activation of Epidermal Growth Factor (EGF) 
and administering Iressa increased average life expectation from 
one to two years, a 100% increase. However, this claim is debatable 
as a study failed to show any survival benefit. 
At a glance, development and commercialization of 
biopharmaceuticals appears to be straightforward as the biology 
of endogenous compounds, clinical and safety profile often are 
well known. However, given by tremendous recent advances in 
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genetic understanding, biotechnology and knowledge of protein 
function, an explosion of novel opportunities for development of 
biopharmaceuticals is definitely a great opportunity to the many. 
The complexity of pharmaceutical development, manufacturing 
process, competitive landscape, funding, commercialization issues, 
and meeting regulatory requirement are of a tremendous challenge 
in the development of novel biopharmaceuticals, to bring them to 
the market and finally to the ensure real benefits reach the patients.
MONOCLONAL ANTIBODIES, THERAPEUTIC  
PROTEINS & VACCINES
Post genomic era has been accomplished by many new inventions. 
Despite the few blockbusters success many products or associated-
corporate failures were unknown to general public. Products 
manufactured by using of biotechnology methods, intended 
for pharmaceutical purposes, have been commonly referred as 
“biopharmaceuticals” or “biodrugs”. Biopharmaceuticals are 
closely related with biological sources usually involving live 
organisms or their active components. Biopharmaceuticals include 
monoclonal antibodies, proteins produced by recombinant or cell 
culture technologies, vaccines, blood or plasma derivatives, and 
cell/tissue culture have changed the pharmaceutical landscape 
tremendously. The methods used in identification, development, 
production, and delivery of biopharmaceuticals differ often from 
methods used in traditional pharmacology (Lievonen, 1999). 
Currently, many biopharmaceutical products have been well 
received by target market and dominated mainly by monoclonal 
antibodies (MAbs), therapeutic proteins and vaccines.
7 ❘❘❚ 
Mohd Azmi Mohd Lila
Monoclonal Antibodies (MAbs)
In contrast to polyclonal antibodies, MAbs are known to specifically 
recognise and bind to a single type of antigen. They are typically 
made by fusing myeloma cells with the spleen cells from a mouse 
or B-cells of rabbits that has been immunized with the desired 
antigen. The antibody molecules contain 2 heavy-chains and 2 
light-chains. There are several various types of MAbs: 1) Murine: 
A murine antibody is one in which both chain types are of mouse 
origin; 2) Rat: Both chain types are of rat origin; 3) Chimeric: In 
a chimeric antibody both chain types are chimeric as a result of 
antibody engineering. A chimeric chain contains a foreign variable 
domain (V-D-J REGION) (originating from one species other than 
human, or synthetic) linked to a constant region (C-REGION) of 
human origin; 4) Humanized: A humanized antibody is one in which 
both chain types are humanized as a result of antibody engineering. 
The complementary determining regions (CDR) of the variable 
domains are foreign (originating from one species other than human, 
or synthetic) whereas the remaining chain is of human origin; 5) 
Human: In a human antibody both chain types, and the J chain in 
the case of polymeric antibodies, are of human origin. 
Current estimated value of the global MAb market is more 
than $38bn represented by ophthalmic (24%), anti-viral (8%), anti-
cancer (32%) and anti-TNF (26%). Currently in the pipeline are 
antibody therapies for almost every form of cancer. Monoclonal 
antibodies have been used to treat cancer for the past decade and 
are one of the most promising treatment options presently available. 
As new cancer-associated antigens are discovered, scientists are 
developing antibodies to target them. The use of antibodies to treat 
cancers is preferred for three main reasons: 1) many view antibody 
treatment as a form of ‘passive immunotherapy’ because the cells 
are made in the laboratory rather than in the patient’s body; 2) As 
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opposed to traditional chemotherapy, which is non-specific and 
can therefore result in debilitating side effects, antibody treatments 
can be targeted directly to the affected cells, thereby reducing the 
side-effects; and 3) most important, they have been shown to work 
experimentally, clinically and acceptable post-marketing feedback.
There are two forms of MAbs preparation: naked MAbs and 
conjugated MAbs. The later is prepared by joining suitable MAbs 
to a well known chemotherapy drug, radioisotope or toxin.
Naked MAbs 
Naked MAbs are the most commonly used and in cancer treatment. 
They often attach to malignant cells, acting as a marker so that the 
body’s immune system can recognize and destroy them. Examples: 
1) Rituxan (rituximab by Biogen-Idec/Roche/Genentech/Chugai) - a 
murine/human chimeric antibody that targets CD20, a protein that 
is present on more than 90% of B-cell lymphomas. It is primarily 
indicated for the treatment of non-Hodgkin’s lymphoma (NHL) and 
for a number of specific indications within this overall diagnosis; 
2) Campath (alemtuzumab by Genzyme/Bayer) is a recombinant 
DNA-derived humanized MAb that is directed against the cell 
surface glycoprotein CD52, which is expressed on the surface of 
normal and malignant B and T lymphocytes, NK cells, monocytes, 
macrophages and tissues of the male reproductive system. It is 
currently indicated for the treatment of refractory B-cell chronic 
lymphocytic lymphoma (CLL); 3) Herceptin (trastuzumab by 
Genentech) is a chimeric humanized mAb indicated for the 
treatment of breast cancers over-expressing the HER2/neu protein, 
which is present in large numbers on tumor cells, including certain 
breast cancers. When this protein is activated, it helps the cancer 
cells to grow. Trastuzumab stops the protein from becoming active. 
HER2 over-expression is found in around 25% of primary breast 
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cancers, possibly higher in metastatic cases. HER2 over-expression 
is generally associated with lower responsiveness to cytotoxic 
chemotherapy.  Herceptin was approved for the treatment of HER2+ 
metastatic breast cancer (as either a monotherapy for chemotherapy-
failure patients or in combination with paclitaxel as a first line 
therapy) in 1998; 4) Erbitux: (developed by ImClone) is a human-
murine chimeric IgG1mAb targeted against EGFR, a receptor 
expressed on cell surfaces in many tumor types which is implicated 
in the development of resistance to the effects of chemotherapy. Like 
HER2/neu, EGFR is found on some tumor cells and helps them 
grow and divide. Erbitux was approved for use in combination with 
Camptosar (irinotecan, Pfizer) for Camptosar-refractory colorectal 
cancer patients or as monotherapy for recurrent metastatic colorectal 
cancer in patients intolerant to Camptosar. Erbitux was approved 
for some advanced colorectal cancers and for some head and neck 
cancers; 5) Avastin (bevacizumab, Genentech) is a humanized 
IgG1 monoclonal antibody targeting vascular endothelial growth 
factor (VEGF), a protein normally made by tumor cells to attract 
new blood vessels and facilitate growth of the tumor. Bevacizumab 
attaches to VEGF, thereby blocking it from signaling for new blood 
vessels to form. It helps stop new blood vessel formation in tumors 
and it also may improve drug delivery so that chemotherapy can 
kill more effectively. Avastin was the first anti-angiogenesis drug 
approved for cancer treatment, and is usually combined with cancer-
killing chemotherapy. It was approved in 2004 to treat colorectal 
cancer, and for non-small cell lung cancer in 2006. Even without 
approval for wet age-related macular degeneration, many doctors 
use it for this purpose instead of the more expensive drug Lucentis 
(ranibizumab, Genentech).
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Conjugated MAbs 
Conjugated MAbs are used to carry chemotherapy drugs, 
radioisotopes or toxins specifically direct to target cancer cells. The 
approach shall reduce the potential casualties or damages to non-
target cells. With such high specificity brought to target cells, the 
desired effects shall be much more intense than naked MAbs but the 
same is applicable to the potential side-effects. Conjugated MAbs 
are grouped into radiolabeled, chemolabelled, and immunotoxins: 1) 
Radiolabeled antibodies: Zevalin (Yttrium-90-labeled Ibritumomab 
tiuxetan, CTI Seattle) consists of an anti-CD20 murine-derived 
MAb coupled with a primarily beta-radiation emitting isotope, 
which allows for imaging of the patient and localization of the 
radioimmunoconjugate. The result is a dual action product that 
binds to the target antigen CD20, found on B-cells, initiating an 
immune response against the B-cell non-Hodgkin’s lymphoma and 
concurrently delivering a dose of radiation directly to tumor cells. 
Other examples are Bexxar (Iodine-131-labeled tositumomab, 
GlaxoSmithKline), like Zevalin, consists of an anti-CD20 murine-
derived MAb coupled with a primarily beta-radiation emitting 
isotope, and it is for treatment of certain types of non- Hodgkin’s 
lymphoma that no longer respond to rituximab or chemotherapy; 
and ProstaScint (Cytogen) a monoclonal antibody tagged with 
Indium-111, used to locate prostate cancer. Then a gamma camera 
detects the radiation given off by the radioisotope; 2) Chemolabelled 
antibodies: Several chemolabelled antibodies are currently in 
clinical trials but none is approved for use; 3) Immunotoxins: 
Mylotarg (gemtuzumab ozogamicin, Wyeth) is another humanized 
anti-CD33 IgG4 conjugated to calicheamicin, a potently cytotoxic 
natural product that induces double-stranded breaks in DNA. The 
CD33 antigen is present on most leukemia cells. Gemtuzumab is the 
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only immunotoxin to date approved by the FDA for the treatment 
of cancer. 
Market status of MAbs
Since 1988, beginning with Orthoclone (Muromonab-CD3 by 
Jansenn-Cilag; murine MAb to suppress rejection of transplants), 
approximately 30 MAbs for therapeutic applications are already 
in the market worldwide. Despite reaching the maturity in the 
market, the degree of importance and demand is increased due 
to the specificity of the application intended for target diseases. 
Currently, the value of MAb market globally in circa RM121 billion 
and expected to overtake pharmaceuticals in the near future.
Table 1  MAbs products , pre-marketing 2010
Generic Trade name Indication Company
catumaxoMAb Removab Cancer TRION/Fresenius
ofatumuMAb Arzerra Cancer GSK
efunguMAb Mycograb Infection Novartis
denosuMAb Prolia (onco) Cancer Amgen
motavizuMAb Numax Infection AstraZeneca
Canakinmuab Ilaris Inflammation Novartis
nimotuzuMAb Theraloc Cancer Oncoscience
Therapeutic Proteins
Erythropoietin (EPO)
Erythropoietin (EPO) is a glycoprotein hormone that regulates 
erythropoiesis (production of red blood cells). It produced naturally 
by kidney. As cytokine, it acts on erythrocyte precursors. EPO is 
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important in the brain’s response to neuronal injury and in the 
wound healing process. The recombinant erythropoietin (RhEpo) 
is indicated for treating anaemia patients i.e., for patients with 
kidney disease who are on dialysis; treatment of anaemia who are 
with chronic kidney disease but not on dialysis. Logically, since 
EPO accelerated erythrocytes production it also increases oxygen 
carrying capacity. This fact did not escape the sight of the athletic 
community. It had been used illegally as a blood doping agent 
in endurance sport for performance enhancing and there was no 
direct test to distinguish natural EPO from pharmaceutical EPO 
until year 2000.
Growth hormone (GH)
Growth hormone (GH) is a polypeptide hormone that stimulates 
growth and cell reproduction in humans and other animals. It is 
synthesized, stored, and secreted by the somatotroph cells in the 
anterior pituitary gland. Somatotrophin refers to the native growth 
hormone, while the term somatropin refers to GH produced by 
recombinant DNA technology, and is abbreviated “rhGH”. GH has a 
variety of functions in the body, the most noticeable of which is the 
increase of height throughout childhood. In children, growth failure 
and short stature are the main results of GH deficiency. Common 
causes include genetic conditions and congenital malformations. 
Deficiency can also cause delayed sexual maturity. In adults, 
deficiency is rare, the most common cause being pituitary adenoma.
In human, rhGH is used as replacement therapy in adults with 
GH deficiency of either childhood-onset) or adult-onset. In these 
patients, benefits are varies to include  reduced fat mass, increased 
lean mass, increased bone density, improved lipid profile, reduced 
cardiovascular risk factors, and improved psychosocial well-being. 
rhGH has also been used to treat conditions which produce short 
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stature which are not related to deficiencies in GH, though results 
are not as dramatic when compared to short stature solely due to 
deficiency. Examples of other causes of shortness often treated 
with GH are Turner syndrome, chronic renal failure, intrauterine 
growth retardation, and severe idiopathic short stature. Some 
doctors have started to prescribe growth hormone in GH-deficient 
older patients (but not on healthy people) to increase vitality. While 
legal, the efficacy and safety of this use for human growth hormone 
(HGH) has not been tested in a clinical trial. HGH has been used 
by competitors in sports since the 1970s, and it has been banned 
by the relevant authorities. 
The use of GH has also been studied in raising livestock and 
several efforts have been made to obtain governmental approval to 
use GH in livestock production. These uses have been controversial. 
In the United States, the only FDA-approved use of GH, is the 
use of a cow-specific form of GH called bovine somatotropin for 
increasing milk production in dairy cows.
Genentech (USA) pioneered the first use of recombinant 
human growth hormone for human therapy in 1981. Prior to this, 
growth hormone used to treat deficiencies was extracted from the 
pituitary glands of cadavers. Attempts to create a wholly synthetic 
HGH failed. Limited supplies of HGH resulted in the restriction of 
HGH therapy to the treatment of idiopathic short stature. In 1985, 
biosynthetic human growth hormone replaced pituitary-derived 
human growth hormone for therapeutic use.
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Table 2  Human growth hormone products in the market for 
treating GH deficiency
Company Generic Product
Pfizer RhuGH Genotropin
Novo Nordisk RhuGH Norditropin
Eli Lilly RhuGH Humatrope
Genentech RhuGH Nutropin, Protropin, 
Somatropin, Somatrem
Ipsen RhuGH Nutropin AQ pen, 
Somatropin
Merck Serono RhuGH Saizen/Serostim
Cytokines
Cytokines are signaling proteins and glycoproteins that are used 
extensively as intermediate for inter-cellular communication. 
They are produced by a wide variety of heamatopoietic and non-
haematopoietic cell types and their effects are sometimes strongly 
dependent on the presence of other chemicals. Cytokines are 
critical to the development and functioning of both the innate 
and adaptive immune response. Since cytokines are involved in 
various activities of the immune system, they are considered to 
be immunomodulators. The cytokine family consists mainly of 
smaller, water-soluble proteins and glycoproteins. Cytokines are 
critical to the development and functioning of both the innate and 
adaptive immune response. Cytokines are classified by structure; 
members of the largest group of cytokines are divided into three 
sub-families: 1) Interleukin-2 ( IL-2) subfamily; 2) Interferon 
(IFN) subfamily; and 3) Interleukin-10 (IL-10) subfamily. The 
first of these three subfamilies contains several non-immunological 
15 ❘❘❚ 
Mohd Azmi Mohd Lila
cytokines including erythropoietin (EPO) and thrombopoietin 
(THPO). Since cytokines are involved in immune system activity, 
they are considered as immunomodulators from the therapeutic 
point of view. Novel cytokine-based therapies focusing on different 
immunomodulatory targets have been, and are being, developed. 
Many of these emerging strategies either target, or consist of, 
interleukin molecules. However, no single interleukin has emerged 
as the one to target for modulating the immune system. Instead, 
companies are targeting a number of different ILs as well as 
other cytokines. The market opportunity for specific agents in 
development will depend on the indication(s) for which they receive 
approval. Many of these compounds are being evaluated for the 
treatment of debilitating conditions such as asthma, cancer, and 
certain autoimmune diseases. If they can demonstrate improved 
efficacy and/or safety compared to current therapies, many of these 
novel immunomodulators have the potential to achieve blockbuster 
status.
Table 3  Cytokines in development
Company Target Cyotokine Clinical trial
Cel-Sci Natural human IL-2 and other 
cytokines
Phase III
Neopharm Recombinant protein consisting of 
IL-13 and
cytotoxic agent PE38
Phase III
Protox IL-4 combined with Pseudomonas 
exotoxin
Phase II
Regeneron IL-1 Trap Designed to bind to IL-1 
and neutralize it
Phase III
Renovo Recombinant IL-10 Phase II
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Synta Oral IL-12/IL-23 inhibitor Phase II
ZymoGenetics IL-21
IL-29 Also known as interferon 
lambda-1
Phase I
Preclinical
Vical Gene therapy; DNA
encoding IL-2
Phase I
Insulin and Diabetes 
Insulin
Insulin is the first therapeutic protein used in modern medical 
practice (beginning in year 1922). Bovine and porcine pancreases 
were the main source of insulins. Later the “humanized” form of 
insulin (based on pig insulin) was made by replacing pig-specific 
amino acid with human-specific amino acid. “Non-Halal” insulin 
was an issue until human insulin manufactured from cloned 
human insulin genes. The insulin molecule has been modified 
via genetic modification for various purposes to accommodate 
the desired pharmacokinetics. Several companies have invented 
insulin analogues: Eli Lilly with insulin lispro (Humalog), Novo 
Nordisk with insulin aspart (NovoRapid) and Sanofi-aventis with 
insulin glulisine (Apidra). In contrast to the original insulin, these 
analogues are absorbed very rapidly and the variability of their 
effect is minimized. For long action insulin, Sanofi-aventis produced 
another analogues namely insulin glargine (Lantus) and Novo 
Nordisk with insulin detemir (Levemir).
cont. Table 3
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Type 1 diabetes
Type 1 diabetes, previously referred to as insulin-dependent 
diabetes mellitus occurs most commonly in children or young 
adults and constitutes 5–10% of the diagnosed diabetes patient 
population.  The pancreatic islet beta-cells are destroyed by an 
autoimmune attack and that causes daily needs of insulin injection 
by all type 1 patients. Without an administration of exogenous 
insulin, patients enter diabetic ketoacidosis, which is a potentially 
life-threatening complication of type 1 diabetes. An administration 
of insulin injections is beset with several challenges: 1) Mode of 
administration – except for bucally absorbed insulin and insulin 
pumps, all insulin is self-administered through a subcutaneous 
injection. Although insulin needles are very small (29–31 gauge) and 
relatively painless, injections still pose a significant disadvantage 
for insulin therapy initiation due to patients’ fear; 2) inconvenience 
of use – injections may need privacy for administration, unlike 
noninvasive treatments that can be taken anywhere; 3) weight gain 
and increased cardiovascular risk – a very common side effect of 
standard subcutaneous insulin therapy is weight gain (approximately 
2–4kg or 4.4–8.8 lbs.); 4) Hypoglycemia – although injecting insulin 
is a fast-acting drug delivery method, patient compliance tends to 
be poor due to the inconvenience in their administration, thereby 
leading to poor glycemic control.  
Type 2 diabetes
Type 2 diabetes, previously known as adult-onset diabetes, accounts 
for 90–95% of diagnosed diabetes cases globally and typically 
develops in middle-aged adults. Type 2 diabetic patients have the 
ability to produce insulin but have an impaired response (or insulin 
resistance) to the effects of insulin, which leads to high levels of 
blood glucose. Insulin resistance in Type 2 patients is associated 
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with increased calorie consumption and higher meal frequency, 
which chronically activates the body’s insulin response. This leads 
to a reduced cellular sensitivity to the effects of insulin and higher 
insulin production to compensate and achieve a normal blood 
glucose level. However, the continued positive feedback loop leads 
to an inability of the body to produce enough insulin for maintaining 
a normal blood glucose level. Type 2 diabetes patients generally 
have normal to elevated insulin production. However, for cases 
where this alone is not effective, oral antidiabetics are prescribed, 
which are followed up with insulin therapy in cases where even 
oral antidiabetics are ineffective. Some of these oral drugs act by 
stimulating additional insulin secretion from the pancreas (known 
as insulin secretagogues) or sensitizing the body to the already 
available insulin (known as insulin sensitizers), or decreasing the 
production of glucose from the liver. When all of the available 
agents fail, as in the case of Type 1 diabetics, Type 2 patients also 
require exogenous insulin. The leading drug treatments available 
are sulfonylureas and metformin, both of which are characterized 
by a high level of genericization.  Thiazolidinediones are insulin- 
sensitizing agents used in combination with other oral antidiabetics 
and/or insulin, although they are associated with weight gain and 
are also contraindicated in patients with congestive heart failure. In 
general the insulin dose required in type 2 patients is considerably 
higher than in Type 1, since the underlying insulin resistance is 
overcome only by a greater insulin load.
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Table 4  Global diabetes market, 2007/08
Value USD, millions Growth (%)
Insulin market
Human insulins 12,278 19.7
Animal insulins 16 4.7
Total: Insulins 12,294 19.7
Drugs targeting underlying 
causes
Glitazone 6,217 -7.9
Sulfonylurea 2,001 2.7
Biguanide 1,954 5.9
DPP-IV 1,725 145. 5
Alpha-glucosidase inhibitor 1,057 11.9
GLP-1 700 19.8
Glinide 812 12.7
Total: drugs targeting 
underlying causes
14,465 7.2
Other anti-diabetics 395 16.6
Insulin devices 140 19.2
Total: diabetes market 27,294 12.7
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Figure 1  Relative positions of different types of insulins. 
Bubble size represents sales in USD $m. Sales of intermediate 
and long-acting insulins were 0.31m  
(notappearing in the figure).
Source: IMS Health, 2009
Table 5  Examples of Late-stage diabetes R&D pipeline
Brand Company Mechanism Status
Alogliptin (SYR-
322) 
Takeda DPP-IV Registration
Victoza (liraglutide) Novo Nordisk GLP-1 Registration
Ondero (linagliptin) Boeh r inge r 
Ingelheim
DPP-IV Phase III
taspoglutide Roche/Ipsen GLP-1 Phase III
AVE0010 Sanofi-
Aventis
GLP-1 Phase III
Syncria (albiglutide) GSK GLP-1 Phase III
dapagliflozin BMS/ 
AstraZeneca
SGLT-2 
inhibitor
Phase III
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teplizumab 
(MGA031)
Eli Lilly/ 
MacroGenics
Anti-CD3 
monoclonal
Antibodies
Phase III
otelixizumab Glaxo/Tolerx Anti-CD3 
monoclonal
antibodies
Phase III
Technosphere 
insulin
Mannkind Inhaled 
Insulin
Phase III
Innovation in drug delivery mechanisms, including the use of 
non-invasive insulin therapy does help in making the treatment 
more convenient. The introduction of oral and inhaled insulin will 
make drug delivery more convenient and help in improving patient 
compliance, leading to better glycemic control. Other innovations 
in type 1 diabetes treatment include ongoing research in islet cell 
transplantation and stem cell therapy, both of which are aimed 
at addressing the cause of the disease. Experimentally, caprine 
pancreatic islets have been cultured successfully in vitro and 
optimized for potential future xenotransplantation (unpublished). 
Xenotransplantation for production of insulin
There is limited availability of human donors to provide pancreatic 
islet cells to Type I diabetes patients. Meanwhile, the search for 
alternative islet sources in pancreatic islet transplantation has been 
extended to number of animal species such as porcine, bovine, 
fish, rat, mouse and monkey. Well-established xenotransplantation 
studies have been reported in large animal organ donors, e.g. pig 
and bovine. Whether caprine species could be an alternative donor 
for the source of pancreatic islets for diabetes researches and 
transplantation trials requires optimized isolation and purification 
cont. Table 5
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methods. Despite various influencing factors for the final yield 
of islets, once isolated, islets are fragile and difficult to maintain. 
An early study has shown that caprine pancreatic islets could be 
cultured with desired viability and functionality, and potentially 
could be used as an alternative source of islets for diabetes and 
transplantation researches. 
Figure 2  Dithizone (DTZ)-stained caprine pancreatic islets seen under inverted 
microscope are presented in crimson red in center part of clusters, where b-cells 
are integrated; therefore, DTZ molecule stains zinc in insulin granules and gives 
the islets a distinctive red color. Panel A: Recovered islets from Euro-Ficoll 
density gradients before optimization (black arrows). Purified islets with abundant 
aggregated cells and acinar tissue (white arrows) (magnification x40). Panel B: 
Recovered islets from optimized Euro-Ficoll density gradients. High-purity islets 
yield with few aggregated cells and acinar mass (magnification x40). Islets purity is 
estimated above 90%,while it is performed roughly by proficient observation. Panel 
C: Islets are presented in different sizes and shapes. Hence, the particles larger 
than 50 um are counted as viable and mature islets (magnification x100). Panel 
D: the stain’s color of islets disappeared few hours after staining, washing with 
Hank’s balance salt solution and transferred to culture media (magnification x40).
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Figure 3  Insulin release in response to glucose challenge in isolated 
caprine islets in presence of l-glutamine and theophylline (aa) or absence 
of l-glutamine and theophylline (wa). The islets were exposed to 1.67 mm/l 
glucose (GL1) for 1 h, to 25 mm/l (GH) for a second hour, and finally 
to 1.67 mm/l (GL2) for a third hour. Values are means ± SE. Interaction 
effect between two treatments applied (different glucose concentrations vs. 
presence or absence of l-glutamine and theophylline) in this experiment 
is not significant.
Table 6  The summary of therapeutic proteins in development 
worldwide
Company Technology Status
Oramed 
Pharmaceuticals
Oral insulin delivery technology Phase II
Cytheris Critical immune-modulator for 
immune T-cel l  recovery and 
enhancement in HIV-1 infected 
patients classified as Immunological 
Non Responders (INR)
Phase II
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Flamel Technologies Controlled release 
form of unmodified  interferon alpha-
2b for treatment of chronic hepatitis 
C virus (HCV) REPLAGAL Shire 
Enzyme replacement therapy for 
Fabry BLA (agalsidase alfa) disease 
(galactosidase deficiency)
Phase II
Human Genome Genetic fusion of human albumin 
and (a lb inter feron Sciences 
(Novartis) Interferon alfa using 
proprietary HGS MAA alfa-2b) 
albumin-fusion technology.
Phase II
Biovitrum Recombinant Factor VIII Fc fusion 
(rFVIIIFc) protein for treatment of
hemophilia A. rFVIIIFc is being 
investigated for the potential to 
prolong protection from bleeding 
and reduce frequency of injections.
Phase II
Cytheris S e c o n d - g e n e r a t i o n  r h I L - 7 
in combination  with standard 
antiviral treatment and vaccination 
in HBeAg-negative chronic hepatitis 
B-infected (HBV) patients
Phase II
Teva 
Pharmaceutical
Biosimilar product to Neupogen 
conta in ing  BLA G-CSF for 
reduction in the duration of severe 
neutropenia and the incidence of 
febrile neutropenia in patients treated 
with established myelosuppressive 
chemotherapy for cancer.
Phase II
ERYTech Pharma E n z y m e  f o r m u l a t i o n  o f 
L-asparaginase improved by 
entrapment and protection of the 
enzyme inside homologous red 
blood cells
Phase II
cont. Table 6
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Lundbeck A/S Novel carbamoylated form of human 
erythropoietin (EPO) intended for 
patients with Friedreich’s ataxia
Phase II
Ta s p o g l u t i d e 
Ipsen/Roche 
Weekly glucagon-like peptide-1 
(GLP-1) analogue for diabetes
Phase III
ZymoGenetics PEG-Interferon lambda (IL-29) is a 
novel type 3 interferon
Phase II
Vaccines
Many infectious diseases have been largely controlled (or being 
eliminated in case of smallpox) through mass use of vaccines 
to create “herd immunity” situation. Mass vaccination blocks 
the chain of an outbreak. However, some uneducated members 
of community worry about the potential side effects of vaccines 
without considering their benefits outweigh potential minimum side 
effects. Side effects of approved vaccines, whilst real, whether for 
human or animals, are either far less serious than actually catching 
the disease, or are very rare, and argue that the risk/benefit ratio 
should be based on benefit to humanity (or socio-economic benefits) 
rather than simply on the benefit to the immunized individual. 
Despite the major success of vaccine and vaccination program, 
there remain many hurdles and challenges to develop new vaccines 
especially for common diseases including malaria, HIV and dengue. 
Several companies have invested more than USD200 million to 
develop dengue vaccine in the past 10 years but failed to bring the 
vaccine to the market. Often experimental vaccines elicit an immune 
response that does not actually protect against the disease. What 
is the problem? Most vaccines preferentially cause production of 
antibodies rather than cell-mediated immunity. This works fine for 
diseases caused by toxins (diphtheria, tetanus), or extracellular 
cont. Table 6
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bacterial (pneumococcal), or viruses that must pass through the 
blood circulation system to reach the tissues where they cause 
cellular damage (polio, rabies). However, intracellular parasites 
including viruses while they reside within target cells cannot be 
reached by antibodies. Thus our immune system will recruit immune 
cells e.g., cytotoxic T  lymphocytes (CTLs) to attacks those infected 
cells. Most vaccines failed to induce good cell-mediated immunity 
(CMI). In case of HIV/AIDS, earlier experimental vaccines focused 
on the antibody response and failed. That well explained why 
thousands of patients dying of AIDS despite their high levels of 
anti-HIV-1 antibodies. Certainly, vaccines that elicit only antibody 
response will not protect individual from AIDS.
An alternative to conventional vaccines is DNA vaccines, one of 
new modes of vaccination. The technique involves with introduction 
of DNA molecules encoding the antigen into the body of the target 
patient e.g. via intra-muscular injection. DNA molecules that 
carrying genetic codes cause the desired antigen or protein to be 
produced in vivo. Both cellular and humoral immune systems shall 
response to the specific antigen, and also the immune response can 
be polarized either to TH1 or TH2 immune T-cells. Delivery of DNA 
directly to individual is also applicable for other purposes other 
than vaccination, including gene therapy and diagnostic purposes. 
DNA vaccines have several distinct advantages, which include 
ease of manipulation, use of a generic technology, simplicity of 
manufacture, and chemical and biological stability. In addition the 
target organ can be specifically targeted and the duration of the 
immune response.
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Table 7  Summary of new vaccine technologies
Technology Description
Plasmid 
DNA or DNA 
Vaccine
Vaccine induced good humoral and cellular response 
in animals. Mostly cellular responses seen in cancer, 
HIV-1, malaria. Prime-boost using pox viruses gives 
promising results. Vaccine delivery is by adsorption 
onto gold particles (“gene gun”) or formulated with 
cationic lipids.
Cellular 
vaccines
Dendritic cells are obtained from patients recruited 
in vitro for a few weeks. These cells are primed/
exposed to target tumor lysates of tumor-associated 
antigens - DNA, RNA, proteins or peptides, then re-
administered to patients.
Lipopeptides Peptide antigen attached to lipid moiety of lipoprotein; 
T-cell response induced against HBV and HPV. Being 
tested against HIV-1 Viral vectors ALVAC (canarypox 
vaccine) already used; other pox viral vectors also 
tested in humans include fowl pox vaccinia and MVA 
(Modified Vaccinia Ankara strain).
T r a n s g e n i c 
plants
Antigens for vaccine preparation have been 
successfully expressed in potatoes, tobacco, tomatoes 
and bananas for oral immunization of animals. Safety 
concerns in human is related to the risk of inducing 
tolerance
Vaccine 
delivery 
devices
Include patches, powered injection devices, aerosols 
for powdered vaccines and micro-needles for 
transdermal immunization.
Current vaccine market
Currently, the global human vaccine market is fairly evenly divided 
between pediatric and adult vaccines, each accounts for about 
half of the total vaccine market, valued at $18bn for 2009. In 
volume terms, there is far greater disparity, because most pediatric 
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vaccines are low-cost, commodity items, distributed throughout 
the world including the developing nations through programs run 
by organizations such as the World Health Organisation (WHO). 
It is in the adult sector that scope for market development is most 
clearly apparent, although new pediatric vaccines are also appearing. 
Vaccines have come back into the R&D programs of major 
companies (including Sanofi-aventis, GlaxoSmithKline, Merck 
and Wyeth) in the first decade of the century, as a result of scares 
about avian influenza, bioterrorism and new emerging infections 
like swine flu. In addition the introduction of cancer and rotavirus 
vaccines has greatly expanded the vaccine market. 
Table 8a  Worldwide human vaccine market (USD billion), 
2007-2013
2007 2008 2009 2010 2011 2012 2013
Total Vaccine 
Market ($bn)
19.90 22.20 24.95 28.15 31.90 36.00 40.53
Growth  
(%, year-on-year)
12 12 13 13 13 13
CAGR  
(%, 2007-2013)
12.6
Source: visiongain, 2008
Notes: Data based on ex-manufacturer prices, 2007 figures are actual sales, other 
years are forecasts
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Table 8b Worldwide human vaccine Market (USD billion), 
2014-2023
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Total Vaccine
Market ($bn)
45.30 50.53 55.97 61.43 67.56 72.62 78.09 84.01 90.43 97.38
Growth 
(%, year-on-year)
12 12 11 10 10 7 8 8 8 8
CAGR 
(%, 2013-2018) 10.8%
CAGR 
(%, 2018-2023) 7.6%
Source: visiongain, 2008
Notes: Data based on ex-manufacturer prices, 2007 figures are actual sales, other 
years are forecasts
Vaccine sales claimed a lion share which is 10.4% of the total 
anti-infectives market. There are several key players for vaccines 
in the global market. The “big five” includes Merck & Co, 
Wyeth, Sanofi-Aventis, GSK and Chiron. Merck & Co’s vaccines 
franchise is set to grow from 5-10% annually. The growth is driven 
predominantly by high-income country demand for higher priced 
vaccines, not volume. Increasingly, high income country vaccination 
schedules are diverging from those in low and middle income 
countries. This trends threatens one of the bases for tiered pricing, 
whereby high-income and low income countries bought the same 
products, but high income countries’ pricing covered most of the 
production cost. The companies mentioned above, collectively, 
may have spent at least USD1billion per year on R&D. This growth 
depends mostly on the launch and success of pipeline products 
for HPV (cervical cancer), zoster (shingles) and MMR-varicella. 
Wyeth’s major sales is from its pneumococcal vaccine, Prevnar. 
However, Wyeth has a very thin vaccine pipeline with no products 
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due for launch. Meanwhile, GSK is the leading company in the 
vaccines market, with sales of more than USD 2billion per year 
worldwide. GSK also has the most extensive pipeline of the five 
leading players. The most promising pipeline candidate is Cervarix 
for HPV (cervical cancer). Sanofi-Aventis is trailing marginally 
behind GSK. Recently in the 4th Quater 2010, Sanofi-Aventis 
launched clinical trial phase II in Malaysia and South-East Asia 
for its new dengue vaccine. Meanwhile, Chiron is the 5th largest 
vaccines company, and its major product is Fluvirin, an influenza 
vaccine. 
Vaccine production economics are highly volume sensitive, 
with an average 60% of fixed costs at the manufacturing level 
and 25% fixed cost on per batch basis. Scale is therefore a major 
cost driver. Whilst there is wide variation in the costs to produce 
different vaccines, many of the factors explaining these differences 
are subject to buyer influence. For existing vaccines, multi-dose 
packaging and making appropriate use of those lower cost suppliers 
that are both economically viable and meet quality standards 
enhances affordability. For new vaccines, influencing batch size 
decisions during plant scale-up will enhance affordability.
In Malaysia, GSK has captured the most for sales in pediatric 
vaccines for the government/public market. Whilst the vaccine 
market is currently dominated by vaccines for the pediatric 
population, a major growth driver for the future is likely to be 
increased vaccination amongst the adolescent and adult population. 
Developmental vaccines for booster or catch-up immunization 
against diphtheria, tetanus and pertussis (DTP) are one example, 
as is the development of a zoster (shingles) vaccine by Merck & 
Co. Another growth driver is likely to be the launch of vaccines for 
sexually transmitted diseases (STDs). Examples are GSK’s Cervarix 
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and Merck’s HPV vaccine for HPV (cervical cancer), GSK’s 
Simplirix for genital herpes, and several early-stage HIV vaccines.
It is forecasted that the booming vaccines market will double (or 
more) in the decade starting in 2010. Aside from the new and more 
powerful vaccines that have been hitting the market, physicians and 
pediatricians have been promoting a more proactive use of vaccines 
for the broad population. Governments have proven to be willing 
to accept much of the cost for vaccines since this constitutes an 
effective long-term strategy to reduce the cost of more expensive 
therapies needed to treat the sick.
Table 9  Vaccine preventable human disease statistics
Disease Estimated 
Worldwide 
Cases
Estimated 
Worldwide 
Fatalities
Selected 
Worldwide 
Vaccination 
Statistics
Cervical cancer/
HPV
500,000 (new 
cervical cancer 
2006) 32 million 
for genital warts 
(2005)
250,000 
(cervical cancer, 
2006)
?
Chickenpox & 
Shingles
10 million 
(chickenpox, 
2007)
2.5 million 
(shingles, 2006)
10,000 
(chickenpox, 
2007)
?
Cholera 240,000r (2006) 6000r (2006)
Diphtheria 4000r (2006) 5000r (2002) 79% of 1-year 
olds (worldwide, 
2006)
Haemophilus 
influenzae
type b (Hib)
4 million (2006) 400,000 (2006) 22% of 1-year 
olds (worldwide, 
2006)
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Hepatitis A 1.5 million 
clinical cases 
(2003)
5000 (2003) ?
Hepatitis B 350 million 
chronic carriers 
(2002)
600,000 (2002) 60% of 1-year 
olds (worldwide, 
2006)
Influenza 1 billion (2005) 400,000 (2005)
Japanese 
encephalitis
50,000 (2006) 15,000 (2006)
Measles 20 million 
(2006)
200,000r (2006) 80% of 1-year 
olds (worldwide, 
2006)
Meningococcal 
diseases
500,000 (2002) 50,000 (2002) ?
Mumps 20-30 million 
(2007)
2000-3000 
(2007)
?
Pertussis 60 million 
(2007)
350,000 (2007) 79% of 1-year 
olds (worldwide, 
2006)
Polio 2000 (2006) <1000 (2002) ?
Rotavirus 
diseases
> 1 billion 
(2006)
500,000 (2006) ?
Rubella >100,000 cases 
of CRS* (2006)
? ?
Streptococcus
pneumoniae 
infections
>20 million 
(2007)
1 million (2007) ?
Tetanus 500,000 (2007) 50,000 (2003) 70% of 
pregnant women 
(worldwide, 
2006)
cont. Table 9
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Tick-borne  
encephalitis 
fever
13,000 (2007) 50 (2007) ?
Tuberculosis 8 million clinical 
cases (2006)
1.6 million 
(2006)
87% of infants 
(worldwide, 
2006)
Typhoid 17 million 
(2000)
600,000 (2000) ?
Yellow fever 200,000 (2006) 30,000 (2002) 48% of infants 
in at-risk areas 
(2006)
Source: visiongain and WHO, 2008
Notes: r = number of cases reported to WHO,. All other data are based on estimates.
* CRS = congenital rubella syndrome
Table 10  Selected human diseases currently without a vaccine
Disease Cases per year E s t i m a t e d 
Fatalities/Year
Cancer* 25 million (2005) 8 million (2005)
Dengue fever 50 million (2007) 10,000 (2007)
Epstein-Barr virus 95% of world population 
infected (2007)
?
Helicobacter pylori 
infection
3 billion infected (2007) ?
Hepatitis C 170 million infected and 3-4 
million new cases (1999)
?
Hepatitis E >100,000 (2007) >1000 (2007)
HIV/AIDS 33 million infected (2007) 2 million (2007)
Malaria 500 million clinical cases 
(2005)
1-3 million (2005)
cont. Table 9
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Nosocomial infections, 
e.g.:
•	 Clostridium 
difficile
•	 Staphylococcus
•	 Pseudomonas 
aeruginosa
•	 Enterococcus
C. diff icile:150,000 (US 
and Europe, (2006) MRSA: 
100,000 (US, 2005)
MRSA: 20,000 
(US, 2005)
Respiratory infections 
n o n - v a c c i n e 
preventable), e.g.:
•	 Group A 
Streptococcus
•	 Group B 
Streptococcus
•	 Respiratory 
syncytial virus 
•	 Parainfluenza
•	 Adenoviruses
>100 million (2007)e.g. >18 
million cases of severe group 
A Streptococcal disease 
(2007); 64 million RSV 
infections (2007)
> 1 0  m i l l i o n 
( 2 0 0 7 ) ,  e . g . 
>500,000 deaths 
from severe group 
A Streptococcal 
disease (2007); 
160,000 deaths 
from RSV (2007)
R o u n d w o r m  a n d 
hookworm Sexually-
transmitted diseases
•	 Chlamydia
•	 Herpes simplex 
virus
•	 Gonorrhoea,
•	 Syphilis
•	 Cytomegalovirus
>1 billion (2006) e.g. 100 
mil l ion new chlamydia 
infections (2007)
150,000 (2006)
Tobacco use 1.25 billion smokers (2005) 5 million (2005)
We s t  N i l e  v i r u s 
infections
4000 (US only, 2007) 100 (US only, 
2007)
Source: visiongain, 2008
Notes: some types of cervical cancer are vaccine-preventable
cont. Table 10
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Veterinary vaccines
The market for veterinary vaccines is spread across species but it is 
limited in size and the development of vaccines is becoming more 
complex and expensive.The global veterinary vaccines market is 
rapidly growing at CAGR of more than 6%, from USD3.8 billion in 
2008, USD4 billion in year 2009 and is projected to reach USD5.6 
billion by year 2015. Forty-one per cent of the market was based 
in the Americas, 37% in Europe and 22% across the rest of the 
globe. Vaccines and biological constitute 14% of the major sector 
of the animal heath market. Others are pharmaceuticals (51%), 
medicinal and nutritional products (35%). Key factors driving 
growth include growing number of diseases in animals, increasing 
public awareness, and technological advancements in biotechnology 
research. Further, the ability of the vaccines to promote growth, 
develop immunity against diseases and lower the rate of mortality 
in the animals is driving sales of veterinary vaccines.
In relation to biological (including biopharmaceuticals), 
vaccine research targets the three major market sectors, cattle, pigs 
and poultry. Vectored vaccines and marker vaccines will become 
widely available.  Broad spectrum anti-mastitis vaccines for dairy 
cattle, anti-coccidia vaccines for poultry and improved multi-valent 
vaccines for cattle, pigs, and poultry will be primary targets.  Other 
major targets are the development of anti -parasite vaccines for ticks, 
nematodes and liver fluke.  In 1994 the world’s first commercially 
available cattle tick vaccine was launched in Australia. Finally food 
safety vaccines are expected to emerge for use against organisms of 
public health significance such as Salmonellae, Campylobacter and 
Listeria.  Advances in delivery system technology will be highly 
significant.  Sustained release anti-microbials and anti-parasitics 
are likely to be offered and oral delivery systems could replace the 
injection of many vaccines.
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Other than protecting animals, animal vaccination helps to 
prevent the spread of disease to humans (e.g. salmonella vaccination 
ensures high quality food is produced from healthy animals) and 
helps to protect the environment. Vaccines, coupled with diagnostic 
tests, eradication programmes and surveillance, help to eradicate 
diseases, e.g. foot and mouth disease (FMD), rabies and Aujeszky’s 
disease in many EU countries. Vaccination also help to reduce the 
annual 17% loss of production associated with disease in animals.
New adjuvants
Traditional vaccines normally employed whole, attenuated or 
inactivated disease causing agents,. Those vaccines were formulated 
with adjuvants and that to induce a more potent and persistent 
immune response. However, to reduce the risk of adverse reactions, 
most of the new vaccines under development are based on well-
defined molecular immunogens. Molecular vaccines include 
proteins, peptides, lipopeptides, plasmid DNA, and recombinant 
viruses based on viral vectors known to be safe in humans. However, 
these vaccines are generally not as immunogenic as traditional 
vaccines. New vaccine targets often require induction of strong 
cellular responses, including enhanced production of T helper cells 
and sometimes cytotoxic T lymphocytes in  addition to antibodies. 
Conventional adjuvants based on aluminum salts mainly induce 
antibody responses, and discovering new adjuvants is crucial for 
the development of vaccines that require cell–mediated responses. 
A rational approach to adjuvant development has been driven by 
improved understanding of the control mechanisms in the immune 
system, and the interplay between the innate and the acquired 
immune response. In particular, the role of toll-like receptors 
(TLRs) in recognizing pathogen-associated molecular patterns 
and the ability to stimulate these receptors using a range of new 
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agonists of varying specificities has significantly advanced adjuvant 
development. Several TLR agonists have been studied as vaccine 
adjuvants in clinical studies. CpG oligodeoxynucleotide (ODN), a 
TLR9 agonist, was shown to be a potent adjuvant of both humoral 
and cell-mediated immunity in human studies. Monophosphoryl 
lipid A (MPL), a TLR4 agonist, has been shown to induce both 
antibody and T-cell responses. It was licensed as an adjuvant for 
hepatitis B vaccine non-responders in Europe. 
In summary, new and improved adjuvants will bring the 
following advantages to vaccines:
•	 The ability to make existing inactivated vaccines more potent
•	 Ability for antigen-sparing,
•	 Stimulation of T cell immunity,
•	 More rapid immunity and longer-lasting immunity
•	 Expanded opportunity for development of therapeutic vaccines.
A key hurdle for new adjuvants is the need for clinical trials 
for new adjuvant-antigen combinations, in order to meet stringent 
regulatory requirements. Therefore, the benefits of incorporating 
any adjuvant into vaccines will need to be balanced against any 
increased risk of toxicity or side-effects
Cancer vaccines
The idea of using therapeutic vaccines against cancers is long-
established, and advances have been made over the past few years in 
developing cancer vaccines using whole-cells, proteins or peptides, 
plasmid DNA, and viral vectors with new adjuvants. Natural or 
synthetic peptides and recombinant proteins as vaccines targeting 
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tumor-associated antigens have shown promising results in humans. 
A peptide vaccine targeting melanoma melanocyte differentiation 
antigens (MART-1, gp100, and tyrosinase), was shown to elicit 
immune responses and prolong relapse-free survival. Tumor cell 
vaccines can be generated from either the patient’s own tissues 
(autologous) or other sources (allogeneic). Dendritic cells can be 
loaded with tumor antigens through the addition of tumor antigens 
to the culture media, either through incubation with autologous 
or allogeneic tumor lysate, gene modification with tumor antigen 
cDNA or autologous tumor mRNA, or creation of tumor cell–
dendritic cell hybrids. A company, Dendreon, has developed a 
vaccine against prostate cancer prepared from a patient’s own 
monocytes and then loaded with a tumor antigen (a fusion protein 
of full-length PAP and GM-CSF). In hormone-refractory prostate 
cancer patients treated with the vaccine, the median survival was 
significantly longer than placebo. An important caveat to the 
foregoing is that cancer vaccines are mostly in the early research 
stage; breakthroughs will depend on an increased understanding of 
what tumor-specific antigens are expressed during the initial tumor 
development stage. 
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Figure 5  Transmission electron micrograph profiles showed 
left: normal nucleus of cancer cells (X5500), center & right: 
VP3 (chicken anaemia virus polypeptide 3)-transfected cancer 
cells (x 7700) - the features of apoptosis showed the shrinkage 
of nuclear membrane and “disintegration” resulting  
cancer cell death. 
Cervical cancer and human papillomavirus (HPV)
HPV vaccines offer protection against the pathophysiological 
effects of HPV infection and HPV-infection-induced cervical 
cancer. Cervical cancer is the second most common cause of death 
among women with 470,000 new cases reported every year, leading 
to 233,000 deaths annually. HPV is a sexually transmitted virus, 
and it is estimated that nearly 50% of sexually active people will 
contract it at some time in their lives. In most cases, the viruses 
are neutralized by the immune system over a period of two to three 
years. In the others, HPV causes genital warts, which may increase 
in number and possibly turn cancerous. Nearly 90% of all cervical 
warts are caused by low-risk varieties of HPV, namely types 6 and 
11, while 70% of all cases of cervical cancers are caused by the 
high-risk types 16 and 18. Vaccination is the best solution to HPV 
infection and its effects, as no cure exists.
41 ❘❘❚ 
Mohd Azmi Mohd Lila
Vaccine development for immunosterilisation  
ZP3 protein is an extracellular elastic coat that surrounds the 
vitelline membrane of mammalian oocytes. The function of 
ZP3 includes serving as sperm receptor inducing the acrosome 
reaction, and preventing polyspermy. Therefore, due to its critical 
roles in fertilization, it has been selected as candidate antigen for 
immunocontraceptive vaccine.
ZP3 DNA vaccine
The recombinant constructed is comprised of a mammalian 
expression vector containing gene sequence encoding rat ZP3 
protein, which in turn stimulates the development of specific cellular 
and humoral immune responses directed against the destruction of 
self-ZP3 protein of oocytes.
Figure 6  Experimental immunosterilization of rats with 
anti-ZP3 DNA vaccine. Left: Normal ovarian section showing 
follicular development at different stage. Right: Ovarian 
section of an animal vaccinated with  ant-ZP3 DNA vaccine 
containing low amount of functional follicles  
that producing ova. 
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Figure 7  Experimental immunosterilization of rats with 
anti-ZP3 vaccine. Left: No sperm bind  the ovum treated with 
anti-ZP3 antibody. Right: A sperm directly bound/attached to 
the ovum un-treated with anti-ZP3 antibody
Recombinant adenovirus-ZP3 vaccines
Recombinant adenovirus currently is used for a variety of purposes, 
including gene transfer in vitro, vaccination in vivo, and gene 
therapy. Several features of adenovirus biology have made such 
viruses the vectors of choice for certain of these applications. For 
example, adenoviruses transfer genes to a broad spectrum of cell 
types, and gene transfer is not dependent on active cell division. 
Additionally, high titers of viruses and high levels of transgene 
expression generally can be obtained. The adenovirus vector 
system uses a human virus as a vector and human cells as a host. 
It therefore, provides the ideal environment for proper folding and 
exact post-translational modifications of human proteins.
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Figure 8  Cloning the gene of interest into adenovirus.
Therapeutic vaccines
The term ‘therapeutic vaccine’ is a paradoxical expression, as 
vaccines have always been designed for prophylaxis of diseases in 
healthy individuals. Therapeutic vaccines are designed to improve 
the immunity status of a patient suffering from a pathological 
condition against which the body has insufficient immune control 
or has lost it entirely. These vaccines “teach the immune system” 
to re-tackle the pathological state that originally led to the 
compromised immune system. Of late, this utopian conception 
has captured the imagination of researchers, in both public and 
private organizations. The concept of therapeutic vaccines has 
been extended to several other indications, including those that 
do not result in a compromised immune system. It is also under 
investigation in lifestyle disorders such as smoking and narcotic 
abuse. The biggest risk of therapeutic vaccines is the probability 
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of re-infection, which might lead to catastrophic consequences. 
Therapeutic vaccines in general target a common shortcoming 
of prophylactic vaccines: the inability to generate sufficient cell-
mediated immunity. There are several approaches being investigated 
to generate sufficient levels of humoral and cell-mediated immunity 
in a disease-affected individual. Based on the current approaches, 
therapeutic vaccines may be classified as follows:
Antigen/whole cell vaccines
Vaccines containing inactivated whole cells or antigens or 
parts of antigens (idiotypes) intended to stimulate an immune 
response against the target organism or pathological state. Most 
research on such vaccines occurs with reference to cancer, human 
immunodeficiency virus (HIV) infection, malaria and so on.
Dendritic cell vaccines
Dendritic cell (DC) therapy or DC vaccines are an emerging 
form of immune therapy currently conceptualized for cancer and 
acquired immunodeficiency syndrome (AIDS). DCs are immune 
cells that play a significant role in the recognition, processing 
and presentation of foreign antigens to the T cells. However, in 
most cases these are not usually present in sufficient quantity to 
provide a suitable immune response. DC therapy thus involves the 
harvesting of blood cells such as monocytes or macrophages from 
a patient and turning them into DCs. The processed. DCs are then 
utilized as vectors for the delivery of antigen. The methodology thus 
provides dual advantages, both amplifying dendrite cell numbers 
and delivering antigens.
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Cytolytic viral vaccines
The concept of the cytolytic viral vaccine is currently being 
investigated for the treatment of cancer. The idea originates from 
the observation of tumor regression following viral infection or 
rabies vaccination. Therefore, the ability of the therapeutic virus, 
based on the concept of maintaining a non-pathogenic status, is of 
utmost importance. The idea, however, faces several impediments 
in terms of the availability of an ideal viral particle for vaccine 
development. There has been little success reported from research 
on this front to date. The Phase I trials of the ONYX- 015 virus 
vaccine, investored by the National Cancer Institute, have been 
cancelled due to its lack of efficacy in killing p53-based cancer 
cells as originally proposed.
Translational medicine
Translational medicine (or sciences, TS) is a term meant to convey 
research that is applicable from the bench or laboratory to the 
“bedside”.  But what does this really mean? There are many diverse 
answers would be given by different scientists. Some would define 
TS as an effort to bring novel therapeutic strategies to patients based 
on relevant experimental data.  Others would use TS interchangeably 
with the term “Personalized Health Care”, both of which refer to the 
process of applying molecular insights from the laboratory into a 
clinical setting.  The bottom line is that the concept of TS is really 
pointing to a vision of bringing the right drug to the right patient 
through intelligent investigation of a patient’s profile: whether it be 
a molecular profile or some other differentiating factor.
Superficially, this might sound like an easy approach, but the 
reality is that nothing is as simple as it sounds–especially given 
the diverse nature of biologic systems.  Members of a traditional 
Research or Discovery group rarely focus solely on answering 
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questions that would make a direct and immediate clinical impact, 
such as patient selection or monitoring molecular pathways 
associated with drug target interaction that would help select 
patients, or the most appropriate drug dose level or schedule.  On 
the other hand, Medical Doctors are often focused on clinical 
endpoints where a combined clinical and molecular approach may 
actually transform and accelerate a program.  TS is committed 
to bringing the two groups together. On a daily basis, we ask the 
following basic questions:
•	 What specific biological events or molecular pathways play a 
role in certain diseases?
•	 What biomarker(s) can we monitor to assess target neutralization 
in the clinics?
•	 How can we best use this information to discover and develop 
new therapeutics and associated diagnostics that will help with 
patient selection?
As with any new concept or approach, it takes time to 
implement.  In the end, the added value and benefit that TS affords 
to drug development will ultimately be reflected by the patients 
themselves
SWOT Analysis of  Vaccine Market 
Source: visiongain, 2008
Strengths
•	 High-cost effectiveness and efficacy of vaccines
•	 New therapeutic and addiction vaccine sectors
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•	 New vaccine technologies, e.g. recombinant DNA technology 
and novel adjuvants
•	 Novel vaccine formulations and more convenient vaccine 
delivery methods
•	 New high-margin vaccines backed by innovative marketing 
campaigns
•	 Low prospect for generic vaccine competition 
•	 Personalised vaccines
•	 Opportunity for contract research and development, and 
manufacturing of vaccines in developing countries
Weaknesses
•	 Expensive vaccine research and development process
•	 Difficult regulatory approval process - large clinical trials and 
low toleration of side-effects
•	 Complex vaccine manufacturing process
•	 High barriers for new companies to enter vaccine market
•	 Vaccine market dominated by small number of large players
Opportunities
•	 Large unmet need for vaccines for currently non-vaccine-
preventable diseases
•	 Expanding biodefence and pandemic-preparedness market
•	 Population increase, especially in developing countries, with 
high need for combating infectious diseases
•	 Growth of emerging economies
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•	 Increased funding from governments for vaccination campaigns
Threats
•	 Anti-vaccine campaigns
•	 Lack of societal recognition of part vaccines play in public 
health
•	 Over-estimation by general public of side-effects associated 
with vaccines
•	 Difficulty in distributing vaccines, especially in developing 
countries
•	 Necessity to persuade governments and health insurers to 
reimburse vaccines at a satisfactory price
PATENT EXPIRY, GENERICS AND  BIOSIMILARS 
MAbs such as Herceptin and Rituxan/Mabthera, set to lose patent 
protection by year 2013/15. Based on the present high market price 
charged per patient (e.g. RM60,000 per course of treatment) the 
patent expiry will soon created a gold-rush effect to existing players 
for biosimilars. Globally, biosimilars market grew 5.9% to reach 
a value of approximately RM4.8 billion in 2012 with the top 10 
players representing approximately 15% of the total market. What 
factors fueling the growth? It lies in the demand for the use of 
biosimilar in hard-to-treat disease areas such as cancer, autoimmune 
and healthcare cost containment. Meanwhile, European Medicines 
Agency (EMEA) has legalized a pathway for the approval of 
biosimilars in year 2006. As a result, the regulatory authority 
provides 10 years of patent protection to biologics. The limited 
scope of patent protection for biologics makes data exclusivity 
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periods is crucial for protecting capital investment in biosimilars. 
However, the US is still in the midst of considering a biosimilars 
approval pathway. 
Interestingly, a major strength of the vaccine industry is lack 
of generic competition. Unlike generic drugs, for which there is a 
booming market, generic vaccines will not gain significant market 
share. Vaccines, along with biopharmaceuticals such as monoclonal 
antibodies, interferons and insulin, are protected from generic 
competition by a number of factors:
Although some vaccines have expired patents, numerous patents 
will protect many of the current top-selling vaccines.
Even when patents have expired, a prospective generic vaccine 
manufacturer must face the expensive process of regulatory 
approval. In the major market e.g. US FDA currently does not have 
a process for the review and approval of generic versions of biologic 
products. In markets where there is a regulatory path for biologics, 
cost savings from generic vaccines are likely to be much less 
significant than cost savings from non-biologic generic drugs. This 
is owing to the complexity of the vaccine manufacturing process.
Finally, potential generic vaccines might face competition from 
more efficacious branded follow-on vaccines. All these factors will 
conspire to limit the market for generic vaccines. Generic vaccines 
will remain limited to certain mass market traditional prophylactic 
vaccines. These will be manufactured increasingly by a small 
number of specialised contract manufacturing companies, most 
probably in emerging market economies.
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Table 11  Comparisons between generics and biosimilars
Generics
(Pharmaceutical)
BioSimilar
(Biopharmaceutical)
Product 
features
Small molecules Large, complex molecules 
requiring a proper drug delivery 
system
Production P r o d u c e d  b y 
chemical synthesis
Produced through intensive 
genetic
engineering methods
Development Low technology 
barrier
Signif icant R&D (genetic 
engineering,
cell lines etc.)
Clinical Trials Does not require 
costly clinical
Extensive  c l in ica l  t r ia ls , 
including Phase I trials to prove 
bioequivalence and Phase 
III, to prove bioequivalence 
and  subs t i t u t ab i l i t y  and 
substitutability
Regulation Proper regulatory 
framework
Only Europe has a proper 
regulatory
exists for most of the developed 
pathway for biosimilars approval;
generic markets the US is still 
debating over the legislation
Marketing Generics are sold 
a t  l a rg e  p r i c e 
differential
Sold at low price differential,
discounts (up to 95%) to the 
approximately 25%–35%, to the
innovator drug as the cost of 
innovator drug manufacturing 
is low
P h y s i c i a n 
requirement
Limited detailing 
to physicians
Detailing to specialist and 
physicians
required
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REGULATORY REGIME AND INTELLECTUAL  
PROPERTY (IP)
National Regulatory Authority (NRA)
The main regulatory authority in Malaysia is National Pharmaceutical 
Bureau (NPCB), supported by Drug Control Agency (DCA), under 
the auspices of the Ministry of Health. Five items of legislation 
form the basis for market regulation: The Poisons Act 1952 
(Revised 1989); The Sales of Drugs Act 1952 (Revised 1989); The 
Medicines (Advertisement and Sales) Act 1956 (Revised 1983); 
The Registration of Pharmacists Act 1951 (Revised 1989); and 
The Dangerous Drugs Act 1952 (Revised 1980). Similar to FDA 
(USA) and EMEA (Europe), NPCB is responsible for registration 
applications for drugs and cosmetics; licensing importers, 
manufacturers and wholesalers; post-marketing safety surveillance; 
and the monitoring of adverse drug reactions. NPCB is to ensure the 
safety, quality and efficacy of pharmaceuticals in Malaysia. NPCB-
approved locally-made drugs are also accepted in Organisation 
for Economic Co-operation and Development (OECD) countries, 
illustrating the quality of generic medicines produced in Malaysia. 
Drug registration processes may take 1-2 years duration.
Malaysia registered some 207,911 medicines in total, of which 
154,507 are imports, according to the Ministry of Health’s figures 
released in January 2009. The authority claim that any drug in a 
pharmaceutical dosage form for human or animal use must be 
registered with the agency. This includes products that alleviate, 
treat or cure diseases; products that diagnose a disease; anaesthetics; 
and products that maintain, modify, prevent, restore or interfere with 
normal physiological functions. The regulation does not apply to 
diagnostic agents and test kits for laboratory use; non-medicated 
medical and contraceptive devices; non-medicated bandages and 
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surgical dressings; and instruments, apparatus, syringes, needles, 
sutures and catheters.
Malaysia has supported the alignment of domestic procedures 
with international norms, such as to harmonise procedures within 
the ASEAN region. The Malaysian Pharmaceutical Product 
Working Group (PPWG) is responsible for the task. Currenlty, 
10 ASEAN countries have adopted the common documents on 
technical requirements, the dossier on quality, safety and efficacy, 
administrative data and glossary, and the guidelines on analytical 
process validation. 
Under Regulation 12(1) of the Poison Regulation 1952, where 
any poison (prescription and nonprescription medicines) is sold or 
supplied as a dispensed medicine, or as an ingredient in a dispensed 
medicine, the container of such medicine shall be labelled, in a 
conspicuous and distinct manner, with: the name and address of the 
supplier or seller; the name of the patient or purchaser; the name 
of the medicine; adequate directions for the use of such medicine; 
the date of delivery of such medicine; and where such medicine is 
sold or supplied.
In October 2005, the Ministry of Health issued the requirement 
that all registered pharmaceutical products be labelled with a 
Meditag, a hologram security patch. The Meditag scheme was 
introduced in early 2005 in an effort to attack unregistered copy 
drugs, counterfeits and other healthcare products. Under the 
guidelines, anyone who fails to abide by this law will be subject to 
a fine, imprisonment or both. First-time offenders will be fined up to 
RM25,000 and/or jailed for up to three years. Any corporate entity 
failing to abide by this law will also be charged a fine of RM50,000 
for firsttime offenders, or RM100,000 for subsequent offenders. 
The Meditag scheme will involve the participation of enforcement 
officers, who will conduct visual scans of the symbols and markings 
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on the Meditag device, as well as verify the manufacturer’s serial 
number. The authenticity of the hologram can be confirmed by 
examining it with a special decoder and a microscope. 
Rules covering veterinary medicines were implemented in 2007 
and plans have been drafted for active pharmaceutical ingredient 
(API) laws. The API regulations will attempt to combat the usage of 
sub-standard and un-approved raw ingredients, thereby minimising 
the problem of adulterated medicines in the supply chain.
IP and Compulsory Licensing in Malaysia
Malaysian government has made several major revisions on patent 
law e.g. in year 2001 and 2003. Despite tremendous efforts to 
improve patent protection in Malaysia, the amendment has yet to 
satisfy international drug manufacturers. Malaysian government 
has guaranteed 20 years of protection for pharmaceutical patents. 
In addition, the government has also implemented the following 
legal provisions: 1) The limited manufacturing, use and sale of a 
generic drug before the expiry of the original’s patent should no 
longer be considered patent infringement; 2) Provisions allowing 
the licensing and production of medicines by the government under 
certain conditions, without the patent holder’s consent. Meanwhile 
PhRMA (USA) has criticised the Malaysian government on several 
issues: the  high level of counterfeiting products in the Malaysian 
market despite the introduction of holograms on pharmaceutical 
packaging), the difficulty in applying process patents, the lack of data 
exclusivity (which has not been aligned with the TRIPS agreement) 
and the overall poor standard of regulatory enforcement,  the lack 
of patent linkage as part the registration process (which has led to 
instances of generic products being launched while original patents 
are still in effect), the need for products bought by the government 
to be listed on a purchases list (the ‘Blue Book’, which requires a 
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lengthy application process i.e. 24 months) due to the infrequent 
meetings of the supervisory body, local companies often obtaining 
market authorisation faster than imports, and  the bioequivalence 
for generics is limited to a number of therapeutic areas, leading to 
further accusations of bias against foreign producers. Estimated 
annual losses related to lax patent protection and other IP issues 
in 2005, is about 8.4% of total sales Malaysian government has 
changed data exclusivity laws for new chemical entities to five 
years and for new indications from the date of approval in the 
country of origin to three years, this still falls short of international 
requirements, as Malaysian approval is often delayed.  Malaysia has 
already issued compulsory licences to Indian drugmaker Cipla for a 
supply of anti-retrovirals (ARVs) in the management of HIV/AIDS. 
The original inventor drug suppliers were US-based Bristol-Myers 
Squibb’s didanosine and UK firm GSK’s zidovudine and lamivudine 
+ zidovudine. This has drive down prices significantly, from RM 
1,200 to RM200, then RM150 per month/patient. Such action by 
our government has made ARVs affordable to the vast majority of 
the population and it affects the profit margin of innovator drugs 
significantly.
MALAYSIAN MARKET AND  BIOPHARMACEUTICALS
The Malaysian biopharmaceutical market is relatively 
underdeveloped. The market is based on imports of branded and 
patented products (mostly from the US, Japan and Germany). Slightly 
more than 0.5% of GDP is from spending on pharmaceuticals.  The 
overall market value is about RM 4billion and expected to increase 
7% per year. Imports will continue to dominate the Malaysian 
market, and the big market share will be with MNC. 
Malaysian government has prompted new regulations targeting 
to stimulate the generics market. If this is going to be a success, the 
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government is expected to significantly lower down their spending 
(minimum average 50% of selected innovators’ drugs) on healthcare 
(supported by studies conducted by School of Pharmaceutical 
Sciences, Universiti Sains Malaysia, 2009). However, the response 
from industry players in Malaysia insofar has been very modest. 
Generic products are poorly marketable compared to well branded 
innovators’ drugs were viewed by practitioners as superior in 
quality. However, as patent protection on about 50 products, with 
high sales figures, will expire within the next 5 years, generics are 
expected be hot products to be produced manufacturers and this is 
in line with initiatives declared under Economic Transformation 
Programs (ETP) 2010/11. The rising quality of generics, cost-
containment needs and implementation of the ASEAN Free Trade 
Area (AFTA) agreement, with products from signatory countries 
to be exempt from import barriers and tariffs are expected to be 
the main drivers for generics/biosimilar. Meaning, existing players 
who are early prepared will be in the best position to capture the 
market. However, the government’s plan to introduce price ceilings 
on essential drugs would be negatively reflected in the value of 
the generics/biosimilar. The market value of generic products are 
expected to grow at a CAGR of 10.51%  to reach RM1.67billion 
at the expense of patented drugs.
Table 12  Generics Market and Forecats
2004 2005 2006 2007 2008 2009f 2010f 2011f 2012f 2013f
G e n e r i c s /
biosimilar 
m a r k e t 
(RM)
0.713 0.770 0.839 0.903 1.031 1.131 1.231 1.409 1.562 1.699
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G e n e r i c s /
biosimilar 
market as % 
total market
24.0 24.3 24.6 24.8 25.0 25.9 26.4 27.6 28.1 28.5
f = forecast. 
Source: IMS Health Asia, BMI
SWOT for Biopharmaceutical in Malaysia
Source: Business Monitor International Ltd , 2009
Strengths 
•	 Increasingly progressive government policy, aimed at attracting 
•	 Improving local manufacturing standards
•	 Commitment to biotech sector development
•	 Robust market growth in recent years
•	 Absence of price controls in the private sector
•	 Sizeable generics market, founded on low patient purchasing 
power and traditionally lax patent laws
•	 Prescribing and dispensing presently dealt with by general 
practitioners, boosting
•	 overall values of the prescription market
•	 Manufacturing of halal medicines improving access to other 
Islamic markets in the region and wider
cont. Table 12
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Weaknesses 
•	 Markedly behind South Korea, Singapore and Taiwan in terms 
of pharmaceutical expenditure and foreign direct investment 
(FDI)
•	 Recent reform aimed at increasing generic product development 
worsening operating conditions for multinationals
•	 Local manufacturing output comprising predominantly 
inexpensive, basic medicines
•	 Market reliant on imports, particularly at the hi-tech end of the 
scale, pressuring government finances
Opportunities
•	 Generics sector as an integral factor of market growth
•	 Exports growing in the face of rising regional and global 
demand, as well as increasing trade links 
•	 Strict government drug pricing policy heavily biased towards 
local drug producers  
•	 Increasingly sophisticated pharmaceutical demand
•	 Government desire to prevent and contain disease outbreaks
•	 ASEAN harmonisation encouraging the adoption of Western 
regulatory standards and the improvement of intra-regional 
trade
•	 Investment in the biotech sector development supported by 
government initiatives
•	 Malaysia becoming an attractive location for medical tourism
•	 More transparent legislation and the attraction of foreign 
investment
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•	 Pending FTA with a number of key trading partners
•	 Planned investment in the expansion of medical facilities
•	 Malaysia offers a considerable contract manufacturing 
opportunities
Threats 
•	 Existence of a significant counterfeit drugs 
•	 Encouragement of parallel trade
•	 Increased focus on internationally recognised norms and 
legislation to disadvantage of local players
•	 Possible introduction of price ceilings on essential medicines
•	 Government seeking compulsory licenses for patented drugs
MANUFACTURING OF BIOPHARMACEUTICALS
The Stages of  Biopharmaceutical Development 
The pharmaceutical industry is the most highly-regulated industrial 
sector. No medicinal product can be placed on the market without 
receiving prior authorization from the regulatory authorities 
responsible for evaluating the quality, safety and efficacy of the 
product. All pharmaceuticals on the market are required to be 
manufactured in premises which are inspected to ensure compliance 
with strict Good Manufacturing Practices (GMP). 
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Figure 9  Biopharmaceutical drug development and 
milestones towards commercialization
Preclinical and Stages of  Clinical Trials
Pre-clinical trials
Pre-clinical research consists of laboratory screening of molecules 
(bioassays and animal tests) to evaluate their therapeutic potential 
and toxicity.
Phase I clinical trials
Studies usually conducted in a small number of healthy volunteers. 
They aim to establish safety at a given dose level and information 
regarding absorption, distribution, metabolism, excretion, including 
bioavailability and the pharmacological aspects of the drug’s action. 
For some conditions (e.g. cancer) Phase I trials will be carried out 
only in patients with the target disease.
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Phase II clinical trials 
Studies conducted in a limited number of patients suffering from 
the target disease. These may initially be open studies providing 
evidence of general activity and efficacy, establishment of an 
effective dose range and frequency of administration. Patients will 
be carefully monitored for all possible side effects. Later Phase II 
studies will use larger numbers of patients and will generally be 
double-blind studies making comparisons with a placebo.
Phase III clinical trials
Studies involving large numbers (several hundred to several 
thousand) of patients with the target disease and often a long period 
of administration. There will be comparisons with established 
medicines for the target disorder. Such studies will provide further 
documentation of any side effects, toxicity and general safety of the 
medicine and may be used to check for interactions with any other 
medications patients are likely to receive concurrently. 
‘Phase IV’
Post-marketing surveillance scrutinising new drug usage and 
clinical trials carried out after marketing. These studies aim to 
determine whether previously unrecognised adverse effects or 
abuses occur, or whether there is a change in the occurrence of 
known adverse effects. Such work may also reveal if there are 
differences in effectiveness of the medicine for labelled indications 
under circumstances of widespread usage or if new therapeutic 
indications of the medicine can be recognised. The definition 
excludes studies in support of marketing.
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GMP Manufacturing Process
Once a production method is established and scaled up, 
biopharmaceuticals can be produced in bulk (large batches). This is 
done by growing host cells (if active proteins desired are expressed 
by mammalian cells or microbes) that have been transformed to 
contain the gene(s) expressing the protein(s) of interest in highly 
controlled conditions in large stainless-steel tanks also called 
fermenters. The cells are encouraged to propagate and stimulated 
to produce the target proteins through precise culture conditions 
that include a well defined balance of temperature, oxygen, acidity, 
media components and other variables ultimately influencing the 
cells behavior. After careful culture the proteins are isolated from 
the cultures, stringently tested at every step of purification, and 
formulated into pharmaceutically-active products. 
The Upstream Process includes all processing steps from cell 
expansion from the origin master cell bank (MCB) through to the 
bulk product. The operations that include the expansion of the cell 
population (and viral population, if applicable) and the biosynthesis 
and harvest of the product comprise the major components of 
the Upstream Process. These steps usually occur in roller bottles 
and bioreactors, but may also occur in whole plants or animals 
(transgenics) or in micro-scale vessels (cell and gene therapies). The 
Downstream Process includes all processing steps and operations 
from the bulk product through to the final product. Downstream 
operations involve the separation of the therapeutic product from the 
culture medium via filtration, chromatography techniques, followed 
by concentration, purification and formulation of the final product.
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Figure 10  Biopharmaceutical drug development and 
production scheme
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The Importance of  Process Integration
A successful and cost-effective biopharmaceutical process can only 
be developed if all areas involved have a broad understanding of 
the impact of upstream process decisions on all downstream steps. 
Close communication, particularly in the early phases ensures 
that holistic processes that consider the entire process stream are 
developed, rather than a series of locally optimized steps that have 
little synergy with one another. Improvements in one step can easily 
be lost downstream without adequate process integration. One form 
of process integration is the combination of downstream separation 
operations into single separation steps. Modifying the product by 
adding affinity or fusion tags, may allow selective purification. It 
is important not just to consider the affinity separation, but also to 
ensure that the product can be adequately separated, and determine 
whether the affinity component can be easily regenerated and 
reused. Process scientists aim to select a host expression system 
with great product yield and a contaminant spectrum that is most 
orthogonal to the product in terms of physical properties. Many 
biotechnology companies express the same product in multiple 
hosts at the same time and choose the best system based on several 
parameters - not just highest expression level. Hosts can be screened 
for product stability, growth kinetics, expression yields, ease of 
downstream processing and contaminant composition. It is often 
advantageous to take the time to improve the host rather than invest 
in additional capital equipment and additional separation steps to 
remove troubling contaminants. Modern proteomics and genomics 
techniques allow the expression scientist to build a better host. This 
requires the downstream processing scientist to be involved in the 
host selection process to give input on desirable characteristics from 
a processing perspective.  The culture type and operating mode can 
heavily impact downstream purification. Therefore the downstream 
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process needs to be flexible enough to handle an increase in 
throughput, because cell clone, media and cell culture parameters 
can all be optimized to substantially increase the amount of protein. 
One of the best examples is production of current influenza 
vaccines which is a cumbersome and antiquated egg-based 
production process. The egg-based method of vaccine production 
for flu vaccines for example is in place since the 1940s. It requires 
significant starting material, at least six months for production, 
and is extremely susceptible to contamination events. These 
inefficiencies can interrupt the supply of vaccines and heighten 
public vulnerability to disease. The change to a cell- or tissue-based 
culture system, begun as long ago as the 1980s, helps to mitigate 
several of these issues and ensure an adequate supply of vaccines. 
Growing vaccines in cell- and tissue-based systems alleviates 
the need for long lead time and can allow for better control and 
scale-up during manufacturing. Cell-based vaccines also have the 
added benefit of increased tolerability, as allergic reactions to egg 
components would no longer be an issue.  For example, Novartis 
has shifted to cell-based vaccine and Abbott’s acquisition of Solvay 
further signal the shift toward cell-based production systems. 
VaxInnate is also developing a cell culture-based E. coli bacterial 
system to produce influenza vaccine that is, currently, in trials. 
The recent flu threat had caused the influenza market expanded 
rapidly. This growing commercial opportunity has encouraged 
companies to develop new technologies and increase manufacturing 
capacity for influenza vaccines and antivirals. The influenza sector 
has benefited from the increased disease awareness and funding due 
to the pandemic flu scare. Maintaining this market momentum in 
the coming years will be a major challenge, and it is likely that new 
technologies in manufacturing, adjuvants and delivery will drive 
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increased product differentiation in the flu vaccines market, and 
perhaps evolve it into a premium-priced area.
However, the high fixed cost associated with the manufacture 
of vaccines and long-term return on investment serve as major 
reasons why more companies have not ventured into manufacturing 
of vaccines.  Thus, any initiatives towards developing new vaccine 
production methods must be driven  toward a new approach in 
which vaccines are manufactured quickly, at a lower cost, and by 
more players globally. 
Figure 11  Process sequence to build a GMP manufacturing 
facility for biopharmaceuticals
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Figure 12  Typical Planning to build a pilot plant to produce 
biopharmaceutical bulks
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Figure 13  Typical timeline to building a pilot plant to produce 
biopharmaceutical bulks
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Figure 14  General concept of plant layout to produce 
biopharmaceutical bulks
Consolidation of  Biopharmaceutical Industry
The driving forces behind consolidation of biopharmaceutical 
industry are due several factors. The cost of production will never 
go down. Thus it exerts cost-containment pressures particularly the 
larger pharmaceutical companies are facing growing costs from 
research & development and marketing. Furthermore, the global 
competition between traditional pharmaceutical companies is 
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accelerated by the changing economical realities of the healthcare 
systems world-wide. Next, increased complexity of clinical trials 
had caused clinical trials are becoming increasingly difficult to 
manage. The existence of global pharmaceutical giants demands 
simultaneous clinical trials in a number of countries. This in 
turn requires qualified personnel with abilities to organise the 
regulatory procedures and the development and maintenance of 
complicated information technology systems. Such an extensive 
infrastructure will result in high fixed costs that work against the 
cost-containment strategy. This has opened new possibilities for 
the dedicated outsourcing services. Thus, the most important factor 
for consolidation is increased versatility of outsourcing services. 
The areas most often outsourced are: 1) R&D, 2) clinical trials, 
3) manufacturing and packaging, 4) marketing, 5) distribution, 
and 6) expert services (knowhow). The quality and availability of 
outsourcing services is important if the company neither capable 
nor willing to build and maintain all the required facilities of 
pharmaceutical product development and manufacture. For 
example,  many of the small biotechnology firms have the facilities 
and expertise to produce gram amounts of biopharmaceuticals, but 
in the clinical trials the needed amount grows to kilogram range. 
This requires special manufacturing plants that meet the strict NRA 
requirements. The cost of building multipurpose GMP facility is 
RM70million (USD25million) to RM170 million (USD75million), 
and many biotechnology firms, with the risk of their new product not 
getting market approval are reluctant to finance a facility but rather 
are willing to outsource their production to contract manufacturers 
who are either dedicated service companies or firms selling excess 
capacity.
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Reducing Time-To-Market
Contract manufacturing organization (CMO) approach
Increasing costs is one of major challenges confronting 
pharmaceutical and biotechnology companies. Thus, reducing 
time-to-market is an essential particularly when the end of 
patent protection is considered. One of the best option is to by 
partnership with a CMO that provides intelligent concepts and 
the proper experience, not only with respect to the production 
itself, but also with regulatory authorities. The time involved can 
also be significant. As many as twelve years can elapse between a 
discovery that seems to have therapeutic value and the approval of 
the new drug. The processes of discovery, development, testing, 
manufacturing and securing approval are demanding and require 
close cooperation among experienced partners Franklin’s advice 
also speaks of the money lost when time is not used most effectively. 
Time is doubly important for drug development. Not only are the 
costs of testing and approval great, the entire economic profile of 
a potential drug also depends on time. Patents enable companies to 
recoup the costs of discovery and development, but the duration of 
a patent is limited; once it expires, the original manufacturer must 
compete with companies that have not had to pay for the costs of 
bringing a compound to market. Thus the incentives to have the 
longest possible period of patent protection are strong. The best 
way to lengthen that period is to move through the development 
and regulatory approval process – particularly the production and 
packaging processes – with the efficiency and speed that comes 
from working with an experienced manufacturing partner
Big pharmaceutical companies used to serve as contract 
manufacturing organizations (CMOs) as a last resort solely to 
achieve efficiencies in cost, capacity and time-to-market, or to 
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obtain a specific expertise not available in-house. Today, these 
factors still play a role, but the most dynamic driver behind the 
use of CMOs in the pharmaceutical industry is now the unique, 
innovative, and state-of-the-art process and production technology 
they offer. As a result, contracts between CMOs and pharma/
biotech companies are far more complex than take-or-pay and 
pay-for-service contracts of previous years. Companies are trying 
to establish a greater number of more involved partnerships in 
which there is a wider variety of terms and deliverables, creating 
stronger links between the organizations involved. Moreover, 
these sophisticated partnerships are not restricted to deals made 
between smaller players. Even the largest competitors are becoming 
more creative in their deal structures as they look to minimize 
costs and build greater operational flexibility. Biopharmaceutical 
manufacturing in particular has become a focus area for CMOs as 
the number of new biotechnology-based drugs moving rapidly out 
of development and through the final phases of clinical trials into 
full-scale production, continues to grow at a rate almost twice that 
of conventional drugs. Fast growth, however also brings its own 
inherent challenges which are principally technical in nature. In 
2007, there were at least 400 monoclonal antibodies (mAbs) in 
preclinical development and more than 100 in Phase II clinical trials. 
One of the more optimistic forecasts for the mAbs market suggests 
that these products are set to account for one-third of all drugs on 
the market by 2010, making up around 60% of the pharmaceutical 
sector’s revenue growth by that time. These highly engineered 
proteins are generally produced by mammalian cells and typically 
have far lower yields than, for example, recombinant bacterial 
systems that are used to produce many other types of biologics. 
Monoclonal antibodies generally have a shorter time to market and 
usually achieve higher success rates compared to small molecules. 
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These drugs also face reduced threat from generic competition as 
the regulatory situation regarding biosimilars is still unclear. 
The are two most common models of CMOs: GMP manufacturers 
and those of the testing laboratories. Companies range from those 
that do only one of these to companies that provide the whole range 
of services. Even within each category, they tend to specialize 
around a particular set of skills and services they provide. GMP 
manufacturing requires large capital investments in equipment and 
facilities. In order to remain compliant with GMP operation, these 
facilities must be kept functioning at all times, which requires a 
constant feed of utilities and on-site support staff. This leads to 
a cost structure in which most of the costs, with the exception 
of raw materials, are fixed. CMOs tend to structure their fees to 
cover these fixed costs (plant amortization, utilities and personnel). 
Development and analytical support on the other hand tend to be 
priced as a fee for service. Since many different clients can be 
accommodated by a testing laboratory (unlike a manufacturing plant 
where only one client is present at a time), they make their money 
on the margin from running tests and price by the hour or by the 
test performed. When development is performed by a manufacturer 
in support of future manufacturing work, it is usually billed on a 
time and materials contract, though some manufacturers provide 
these services for a fixed fee.
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Companies providing manufacturing services further 
differentiate themselves by the stage of clinical development for 
which they provide assistance, be it early clinical trial testing 
materials for phase I and phase II development or support of 
phase III and commercial sales. When new commercial approvals 
is slowing down, the market opportunity will be primarily in early 
development and outsourcing the manufacture of clinical-trial 
materials (CTM) is strong and growing. Demand for these services 
mainly stems from the increasing number of phase I candidates. 
CMOs provide biopharmaceutical manufacturers the following 
advantages and flexibility:
•	 Providing manufacturers with immediate access to specialist 
technology platforms and knowledge bases not possessed in-
house.
•	 Relieving strain during the launch of new products and when 
the market size is yet to be determined.
•	 Enabling manufacturers to ‘switch-off’ manufacturing, without 
cost or loss of staff, if a drug is failing.
•	 Enabling manufacturers to quickly manufacture products 
acquired through licensing and/or merger and acquisition 
activity.
•	 Providing assistance for registration and approval processes in 
foreign markets.
•	 Allowing manufacturers to increase the number of clinical trials 
underway, without a commensurate ramp-up in cost.
Engage an expert manufacturer to develop manufacturing scheme
CMO may provide the foundation for all of the manufacturer’s 
projects. The manufacturer’s team that completed development and 
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clinical testing should be involved in commercial manufacturing. 
This shall ensure the intimate knowledge of the compound and the 
filling process is retained when the challenges change from testing 
to commercial production. Continuity also avoids losing time on 
knowledge transfer from R&D to manufacturing team; should any 
difficulties arise, those involved will know the entire history of the 
project. CMO and representatives of commercial manufacturing 
shall review and evaluate product specifications and manufacturing 
requirements as well as technical options. For example, experienced 
manufacturing partners can often apply a process that has already 
been validated, shaving off even more time-to-market. In other 
cases, a new process must be designed, implemented and validated. 
In these situations, the development service’s overall experience 
and continuity with the project will support efficiency and a shorter 
time to-market.
Ideally, once a project starts, a specialized manufacturing team 
begins to work with a team from the manufacturer to form a joint 
development team.  The team defines steps, develops a checklist, 
including milestones to measure progress. The checklist to be 
compiled at this early stage will include all the equipment that needs 
to be ordered in time for the commercial production phase. CMO 
should be able to offer a solution that provides the manufacturer 
with the greatest convenience. At the same time, the solution should 
be one with which the manufacturer has considerable experience, 
as this experience can be brought to bear in increased process 
efficiency.
Integrated project management approach
The main factor in moving a project through development and testing 
efficiently is well-designed, integrated project management. This is 
to ensure all processes are synchronized so that they come together 
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at the earliest possible moment.  For example, once a primary 
packaging system selected, the development team reviews the entire 
filling process – the filling machine, format parts and so on – so 
that it can begin informing the company’s own suppliers who then, 
in turn, can deliver the necessary parts on time. The development 
team also studies the compound’s particular characteristics and the 
packing materials to make sure they are suitable in terms of light-
sensitivity, filling, pumps and other parameters. The checklist and 
milestones developed in the planning stage keep the process on 
track, shortening time-to-market.
Testing feasibility and production
With the preliminary plans in place and a detailed process roadmap 
drawn up, including testing and filling can begin. The first step is to 
perform a small-scale feasibility production activities e.g. filling. 
The small-scale filling shall be done manually and entirely under 
laboratory conditions. It constitutes a feasibility study that serves 
several purposes. Most importantly, it gives a quick indication 
of whether the approach is practical. These small-scale tests also 
determine the specifications of the product, including whether 
it should come in a single-dose or multi-dose packaging, what 
the fill volumes are and which storage conditions are necessary. 
One rule of thumb is that the more information the feasibility 
approach creates, the less time is required for adjustments during 
the commercial manufacture. Adjustments, changes or corrections 
can be performed in the laboratory much more simply than once 
it has gone into operation. Some companies have specialized 
knowledge of very sensitive substances that can bring concrete 
benefits in this phase of development. Whether the results of the 
feasibility study are applicable to big scale manufacturing must 
also be tested and validated prior to commercial manufacturing. 
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To scale up successfully, a number of steps have to be carefully 
evaluated and calibrated e.g. the thawing procedure of the bulk 
product, for example, and the definition of bulk handling and mixing 
properties. Filtration is another important aspect that requires expert 
knowledge. What kind of tubing will be used? What is the right 
tubing diameter? What is the maximum filtration pressure allowed? 
Experience in answering these questions makes the process efficient. 
Final testing and initial manufacturing
Production of clinical batches begins as soon as scaleup success has 
been confirmed. To generate precise indicators for the master batch 
record, a minimum of three batches must be run, using a minimum 
of 10 % of the future commercial batch size. These batches can be 
used for registration purposes. The critical factors in determining 
their success are good manufacturing practices (GMPs), which are 
indispensable, the possibility of human use, which must always be 
borne in mind, and release of the batches by quality control and the 
qualified person. The runs testing the process’ scaling up produce 
material for stability batches, which can also be used for clinical 
studies once the stability tests have produced positive results. In 
the aseptic filling process, each step in a project is geared towards 
greater safety and speed in the final stages. Prior to commercially 
manufacturing the drug, however, a detailed risk analysis must be 
performed for all steps of the process, followed by validation, which 
must be conducted on at least one full batch. All critical parameters 
are examined and tested. These include holding times, mixing 
properties and full-day production (robust processing). Simulating 
worst-case conditions is one way to cover all of these base values. 
Another is to validate an optional minimum and maximum batch 
size to build flexibility into the commercial production process. 
Validation also extends to various shipping aspects, including the 
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container, the packaging and the means of transportation. These 
tests and evaluations produce a validation protocol and report that 
are used for all future commercial batches, and these documents 
are to be submitted to the regulatory authorities.
One of the most effective areas for reducing time-to market 
for a new biopharmaceutical compound is packaging and all of 
the elements surrounding it. The processes involved in this phase 
are precisely planned, and valuable time can be saved. Working 
with an expert manufacturer that has the know-how, expertise, 
and infrastructure to implement the project efficiently can lead to 
significant gains for a drug development company. Experienced 
teams, integrated process management and active communication 
between all units and team members are crucial. Most important, 
however, is careful planning in the earliest stages to ensure that all 
steps in the process are recorded to save as much time as possible. 
An excellent track record with regulatory agencies such as the 
NPCB, TGA, FDA, EMEA and others means that companies can 
rely on the manufacturer’s experience in maintaining the requested 
GMP status and navigating approval channels. The combination 
of detailed technical knowledge, close coordination with project 
partners and deep understanding of materials enables a good 
specialized manufacturer to help its partners improve efficiency 
throughout the development process, ultimately shortening the 
time it takes to bring a new product to market and improving the 
opportunities for sales.
INVESTOR’S PARADIGM
Fulfilling Unmet Needs of  Healthcare
The market for pharmaceutical discovery companies can be divided 
into two parts: in the first market are the investors and potential 
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partners (may be large pharmaceutical companies) to whom a 
discovery company must market its profit potential and development 
projects, and those in the end market are the doctors and patients. 
These two markets are closely linked together. To succeed in the 
first market, issues on who will be paying for the end product must 
be solved first. The successful strategy here is to pay attention to the 
larger pharmaceutical firms that may have an interest in the product 
under development. These well-established firms have little need 
to trumpet their own research, and at the same time they are able 
to invest the resources needed to bring their products all the way 
to the market. To compete with a well-established full-spectrum 
company or a big pharma is quite difficult. The emphasis of unmet 
needs as a key success factor is required strongly by many potential 
investors. Gaining global visibility and credibility is easier when a 
company targets a very specialized sector with clearly unmet needs.
Strong Technology Platform
A high-quality new product process is one of the strongest common 
features of high-performance businesses. It is somewhat difficult to 
differentiate the impact of the number of products in the pipeline 
from the strong platform: the novelty and quality of the platform 
(patents, technologies) are essential to keep the product pipeline 
saturated. It is the innovativeness and therapeutic superiority of 
products that attracts investments to the company. A strong platform 
was understood to constitute possession of wide immaterial rights. 
The importance of a strong platform in the modern virtual business 
structure was stressed by experts. Despite failure to launch its final 
products, companies with a broad IP portfolio will have still a great 
potential to create new value from new application of their IP.
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First to Invent First to Market
Another key factor for a successful company’s products is 
marketing. Again, there are two target groups: the first market (big 
pharmaceutical companies and venture capitals, VCs) and the end 
users of the drugs (doctors and patients). It may even be that the 
product must be marketed to insurance companies, opinion leaders, 
and public health agencies. Planning rapid market penetration is 
essential to any company’s success. Marketing should begin early 
in the product development cycle, and there are a few questions to 
be asked: First, how will the product be positioned in the market? 
This should be expressed in terms of product value and use, and 
it should be borne in mind that the end-product customers are 
primarily doctors and medical personnel. Second, how will the 
product be distributed and sold in both domestic and foreign 
markets? The strategy of the majority of small firms is to form 
alliances with larger pharmaceutical companies, but as companies 
mature and grow their product portfolio, their own sales channels 
should be evaluated. In the interviews marketing of the company as 
a whole was often brought up. The analysis of market positioning 
and profile of the products in every phase of the development must 
be considered as a success factor. The entire product development 
process shall also be considered as the initial phase of marketing. 
A relationship with the potential partners must be built early on 
“to get people interested in what the company is doing” as part of 
a successful product strategy. 
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Figure 15  The pharmaceutical value chain for new 
innovations. Marketing is considered as the biggest proportion 
of the final value to the stakeholder.
Licensing
Licensing deals are a popular way for pharmaceutical companies 
to access emerging, high potential drug candidates. Deals may be 
completed in relatively short order, after a review of the technology 
has demonstrated a potential fit between the goals of the investor 
and developer. Although rising competition for leading biotech 
drug candidates has pushed deal value up and resulted in relatively 
large upfront payments, these nonetheless are usually considerably 
lower than payments made as project milestones are reached. This 
allows termination of the collaboration if and when expected 
progress is not achieved; in practice, project termination is not at all 
uncommon, for licensing agreements that were entered into when 
drug candidates were in a very early stage of development as well 
for later-stage compounds. 
Most licensing agreements now have “no-fault” termination 
clauses that may be exercised by the partner upon 60 or 90 days 
notice. Typically, the investor’s role revolves around financial 
backing of the drug during its development stages; the investor 
may also assume responsibility for regulatory filings as well 
as marketing and distribution once the drug/s is approved. The 
developer usually conducts the hands-on development of products, 
especially for early-stage development deals. This is beginning to 
change, however, with some investors playing a greater technical 
role in the development process. Licensing deals work particularly 
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well when one party has unique soft assets (such as intellectual 
property and scientific know-how) but does not have significant 
hard assets (employees and facility) that could be rationalized in 
an acquisition to extract value. They may be entered into at any 
time during the drug development process, but are most common 
in later stages once a technology has been validated.
The biopharmaceutical business deals are usually licensing 
agreements in which the licensor has a vested interest in seeing 
the licensee succeed in financial and marketing sense. As to the 
terms of payment itself there are no internationally unified systems 
in existence. Even the terminology used is different depending 
not only on the country in question but also on the nature of the 
business deal. However, one can distinguish between the four 
most usual payment methods which are: 1) preliminary or initial 
payment, 2) down payment and annual royalty, 3) annual royalty, 
and 4) milestone payments.
1) Preliminary or initial payment. Preliminary payments are 
compensations made before signing of the agreement for the 
costs caused by, for example, a feasibility study, documentation 
or the development of the licensing offer.
2) Down payment and annual royalty. In this payment method, 
the licensor wishes to gain a sum of money in advance, and 
an annual royalty based on some clause, e.g., level of sales or 
period of time. The larger the initial down payment, the smaller 
the on-going royalty rate.
3) Annual royalty. This is merely an annual royalty payment 
without an initial down payment.
4) Milestone payment. This is not exactly a payment term used in 
the licensing agreements but rather an investment to a project, 
which is done by someone else. For example, an established 
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pharmaceutical enterprise could finance the drug research 
process of a biopharmaceutical firm under the agreement 
that the resulting product is licensed to the established 
pharmaceutical enterprise.
Successful Technology Transfer
Why biotech technology transfer deals fail
Many biotech tech transfers fail to meet the expectations of one 
or both parties.
•	 Project failure can include inability to meet goals on time, 
failure to meet goals on budget, total inability to meet one or 
more key scientific goals under any circumstances, inability to 
meet one or more key business goals, dissolution of the alliance 
prior to previously agreed termination date and/or legal recourse 
by one or both parties against the other.
•	 The failure of a biotech technology transfer can have significant 
implications for both the technology developer and the 
investor, although consequences are usually more serious for 
the developer due to its often smaller size and greater reliance 
upon a single revenue stream.
•	 In contrast, most technology investors have projects in many 
different areas and are not reliant upon a single application or 
approach.
•	 However, because technology investors tend to seek out and 
acquire large numbers of new technologies on a regular basis, 
large numbers of deal failures can, in the aggregate, impact 
their competitiveness.
•	 There are many reasons why biotech tech transfers fail including 
failure to conduct appropriate due diligence, establishment of 
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an inappropriate deal structure, management changes at the 
investor, cultural differences between the partners, project 
organization and differing expectations and technology failure.
•	 While many factors can influence the success of biotech tech 
transfers, analysis of large numbers of such relationships has 
shown that manner of partner introduction and location of 
partners.
Strategies to ensure successful biotech technology transfer deals
•	 For both developer and investor, a successful tech transfer 
means, at a minimum, that the agreement terms have been 
fully satisfied and the contract has been fulfilled without early 
termination or penalty.
•	 Depending upon the scope of the contract, however, both groups 
often have additional criteria constituting relationship success.
•	 With a large and rising number of biotech tech transfer 
agreements each year, both technology developers and investors 
have developed strategies to increase the probability of success.
•	 Strategies to increase biotech tech transfer success for 
both technology developers and investors include tools and 
approaches that address issues of interest to both parties, such 
as techniques that meet technology challenges.
•	 Strategies for biotech technology developers to help ensure 
tech transfer success address the unique challenges faced by 
these groups, including techniques to optimize resources, think 
like a customer, work with professional technology transfer 
organizations and publish prolifically.
•	 As many biotechnology investors are larger enterprises with 
extensive drug development programs that span a broad range of 
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applications, a large proportion have established sophisticated 
processes to identify, consummate and manage appropriate tech 
transfer relationships.
•	 Over the years, these biotech investors have developed best 
practices that address key aspects of relationship success, 
including technology identif ication and due diligence, 
structuring innovative deal terms, addressing compensation 
issues, fostering an entrepreneurial technology developer 
environment, ensuring effective alliance management, 
navigating cultural chasms and addressing international 
intellectual property challenges.
The future of biotech tech transfer deals
•	 Over the next five years, the role of biotechnology in drug 
development is expected to expand strongly as biotech drug 
sales rise by 17.7% per year while small molecule drug sales 
grow by just 2.9% annually.
•	 Through 2015, pharmaceutical companies will continue to 
embrace biotechnology, although this trend will be more 
significant for some companies than for others. Growth will 
be driven by increasing drug development difficulties, ongoing 
patent expirations and international competition.
•	 However, the very high prior rate of biotech tech transfer deal 
value growth is expected to decline from 27.1% per year to 
18.5% per year as technology valuations become more closely 
aligned with actual market potential.
•	 Biotech tech transfer deal volume is expected to continue 
to expand at a moderate pace of about 5% per year; growth 
will be supported by a proliferation of new technologies 
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related to gene therapy but constrained by an ongoing lack of 
commercialization resources, particularly at universities and 
other research institutes.
•	 Licensing will remain the most desirable form of technology 
ownership for tech transfer investors as a relatively weak 
economic environment makes companies less willing to engage 
in risky acquisitions and joint ventures.
Funding Issues
Funding for biotech companies is derived from several key sources, 
to include: direct investment from original founders or promoters, 
in which funding is exchanged for company equity; venture capital, 
a more structured process of exchanging funds for company 
equity; and initial public offerings (IPOs), in which company 
equity is offered to the public through a normal offering of shares 
on a public exchange. In recent years, and particularly following 
the recession of 2008 and 2009, each of these funding sources 
has decreased considerably, resulting in a shortfall of funding 
available for biotech R&D worldwide. In the UK for example, 
78% of respondents found that access to capital had become more 
challenging in the past year, 76% of those seeking to raise equity 
financing experienced difficulty and of these, 37% were unable 
to obtain any funding. While direct investment includes funding 
provided by smaller investors (“friends and family”), it mainly 
comprises larger tranches supplied by professional investors such as 
mutual funds. In the US, these investors typically include specialist 
healthcare funds that understand the drug development industry and 
are prepared to commit greater resources for longer periods of time; 
in Europe, however, they tend to include more generalist mid-cap 
investors who are less well acquainted with the uncertainties of 
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the drug development business. Both types of investors, however, 
have been impacted by the steep decline of global stock markets 
in which equities lost one third of their value between late 2007 
and early 2009. 
Biotech companies have also seen decreased venture capital 
funding. Venture capital funding of US companies declined 
substantially in 2009 compared to prior years, with total funding 
ranging from just $3.3billion to $5.0billionn per quarter, compared 
with $7.4billion to $8.2billionn per quarter in 2007. While the 
biotech sector remained the second highest recipient of venture 
funding after software, receiving $905m to $1.2billion per quarter 
in 2009, this nonetheless represents a substantial decline from 
prior years, when the US stock market was high and the prospect 
of successful initial public offerings (IPOs) for high potential 
biotechnology companies was an attractive draw for investors. 
However, total IPO volume is down sharply, with just 15 US IPOs 
of venture-backed firms in 2008 and 2009 combined, according to 
the National Venture Capital Association (NVCA); this compares 
with 86 such deals in 2007, 57 deals in 2006, another 57 deals in 
2005 and 94 deals in 2004. Even these levels, however, represent 
a significant decline from years past, with more than 250 IPOs in 
1999 and 2000.
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Table 15  Capital raised within the 12 months (2008/2009) by 
type of enterprise in Europe
Source: DTI-biopharmaceutical survey in Europe, May June 2009
Figure 16  Value-focused financial strategy: driving high 
growth and high returns
None/no
capital
€<1m €1 - 4.9m €5-10m €>10m Do not 
know/no 
answer
Total
Number of enterprises
Platform 0 4 1 1 0 0 6
Pre-clinical 1 16 13 1 1 1 33
Clinical
phase 1
1 1 3 2 0 1 8
Clinical
phase 2
2 5 6 3 3 1 20
Later-stage 0 2 1 1 4 0 8
Product(s)
on market
2 1 3 3 3 0 12
Total 6 29 27 11 11 3 87
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ENTREPRENEURSHIP IN BIOPHARMACEUTICAL
Entrepreneurship Characteristics
Entrepreneurism is a characteristic difficult to define. In a sense, 
commitment, team-work, and management skills could be 
understood to be characteristics of entrepreneurism. Entrepreneurial 
personnel must be individuals who can succeed in different 
environments, show tenacity, have a sense of urgency, and who are 
pragmatic and can identify the non-obvious. Every scientist who 
joins a biotech company should realize the fact that it is not all 
about the excitement of science and technology, but about sustaining 
a profitable business and moving forward. Most scientists from 
academia might not agree with this reality as they are not aware 
that their R&D is only a small part of the big value chain and 
funding obtained for their research must be justified towards unified 
objective of value creation. The desired quality of entrepreneurial 
characteristics for biopharmaceutical companies is people who are 
generalists, who are able to do many things (on whatever it takes), 
drivers and they must have the ability to maintain enthusiasm and 
speed in business development.
Management Team
The importance of financial and managerial viability of the 
developer organization cannot be over emphasized in the case of 
tech transfers that will involve an ongoing working relationship 
since the ramifications of avoiding this part of the due diligence 
process can be severe, and include a financial “bailout” from the 
investor should the developer organization not have sufficient 
funding in place. In the worst cases, such relationships will become 
impossible if the developer group simply ceases to exist due to 
a lack of funding or over-reliance on one particular deal. For 
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example, Anevisa filed for bankruptcy in early 2010 after a planned 
merger with Arcion Therapeutics was terminated; the merger had 
included provisions requiring payback of funds from a stock sale 
and the retirement of certain debt. Many technology investors, 
therefore, request financial documents and other materials during 
a formal audit to determine the developer’s ability to maintain its 
ongoing operations over the length of time covered by the tech 
transfer relationship. An audit does not always identify financial 
shortcomings, however, as Hawaii Biotech had not reported any 
financial weakness prior to its December 2009 bankruptcy filing.
Managerial strength can be even more difficult to determine. 
Some investors request personnel files and/or interview developer 
staff in order to ascertain employees’ likelihood of remaining with the 
company; this is particularly important when scientific or technical 
expertise resides with just a few key individuals. Some developer 
organizations demonstrate clear managerial strength. For example, 
Genzyme continues to be named a top employer in a global survey 
ranking the reputations of biotech and pharmaceutical companies. 
In 2009, Genzyme ranked third on the list of 575 companies, the 
second consecutive year it has achieved this position. Genzyme 
placed among the top 10 of all biotechnology and pharmaceutical 
companies in the world for the seventh year in a row. The survey, 
which was commissioned by Science magazine and the American 
Association for the Advancement of Science (AAAS), identifies 
the top 20 companies with the best reputations as employers 
and includes the opinions of more than 2,300 respondents. Such 
measures clearly suggest strong managerial practices and mitigate 
risks related to high turnover,
Management change at biotech companies is not viewed by 
investors as a substantial cause of alliance failure. This is likely due 
to the fact that many biopharmaceutical companies are run by their 
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founders, who often invest many years into developing the company 
and technology; as well as the relatively few areas in which most 
biotechs work. Consequently, relationships with investors are treated 
by most biopharmaceutical companies with the utmost care and 
concern, so that biotech management changes, when they do occur, 
tend not to have a significant impact upon relationships already in 
place. On the other hand, one of the most frequently cited causes 
of alliance failure by biopharmaceutical companies is a change in 
senior management at the investing company. Because such changes 
are often accompanied by a shift in the investor’s research priorities, 
a senior management change can impact the day to day workings 
of an alliance in many different ways that include a:
•	 Change in the scientific and business staff at the investing 
company responsible for the alliance;
•	 Corresponding shift in project expectations and/or workflows;
•	 Reassessment of the biotech partner’s contribution, leading to 
a reconfiguration of each partner’s roles and responsibilities;
•	 Reduction and/or substitution of resources allocated by the 
investor to the alliance;
•	 Change in cultural climate, affecting the ability of alliance 
workers to effectively communicate with each other and with 
partner staff;
•	 Diminished interest in the alliance on the part of the investors, 
even leading to a premature termination of the relationship.
Management changes in the pharmaceutical industry have 
been occurring at a brisk pace as a result of ongoing industry 
consolidation and downsizing. Management changes in investor 
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management can cause changes in the investee company as new 
executives tend to enter new positions with their own project 
priorities. Many equally worthy projects often compete for limited 
company resources and incoming executives may not have a full 
understanding, and therefore appreciation, of the alliances entered 
into by their predecessors. This is particularly true for global 
pharmaceutical companies, which maintain development activities 
in many different areas, working with dozens of partners in various 
capacities. Biopharmaceutical companies are also contacted on an 
ongoing basis by hundreds of biotech companies seeking to enter 
into relationships with them, and often have their pick of partners. 
Challenges and Opportunities in R&D 
Similar to any other biotech companies, biopharmaceutical 
technology developers rely heavily upon external funding to 
continue their operations. They need to develop or acquire new 
technologies to enhance their efficiency and competitiveness. All 
biopharmaceutical developer suffered from an ongoing conflux 
of factors that complicated the R&D process to include more 
complicated and increasingly interconnected disease targets; 
escalating research costs; increased regulatory scrutiny and 
demand for more clinical data; and fewer in-house R&D resources. 
Biopharmaceutical companies often have no saleable products 
to generate cash that will fuel operations, then they must rely on 
investor funding. With ever lower levels of such funding available, 
many are now turning to technology transfer arrangements to 
fund continued operations. In fact, while many biopharmaceutical 
companies initially tried to become fully integrated drug-makers, 
with capabilities spanning the full range of a drug’s lifecycle (R&D, 
manufacturing and sales), this goal for many has proven impossible 
to achieve as the odds of successfully launching an independently 
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marketed therapeutic product proved far lower than expected. 
As this occurred, many of these firms switched gears to become 
research houses and now fund their R&D operations from equity 
capital and the proceeds of alliances with pharmaceutical or larger 
biotechnology companies.
As biotechnology has emerged as a highly successful new 
approach to drug design, technologies have proliferated but 
most have not been fully exploited. While few of these discarded 
technologies represent significant breakthroughs, many offer 
incremental improvements whose inventors were unable to follow 
through with development due to resource constraints and other 
practical problems. This has given rise to an industry of brokers or 
consultant who act as middlemen between biotechnology developers 
and investors, arranging transfer deals. These brokers, who may act 
on behalf of either the technology developer or investor, take many 
different forms and often play several roles; they include:
•	 University or other research institute technology transfer 
offices;
•	 Licensing professionals at biotech and pharmaceutical 
companies;
•	 Independent consultants who take a fee from technology 
investors upon deal completion;
•	 Technology financiers, such as venture capital funds, who act 
as matchmakers for their investees.
The degree to which each type of broker actively pursues 
tech transfer opportunities varies; some are extremely aggressive 
and actively pursue a large number of opportunities. Others are 
more selective. All benefit from a heightened interest among 
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both technology developers and investors in tech transfer and a 
proliferation of new information and networking tools that enable 
this process. These include detailed reports and databases that are 
regularly updated with technology and deal information, industry 
events that bring developers and investors together, and interactive 
tools that permit ever greater levels of information sharing. Brokers 
bring many benefits to the tech transfer process. Importantly, they 
often initiate deals among parties that would otherwise not meet. 
During the subsequent evaluation period, they also maintain deal 
momentum by:
•	 Providing technology, business and other information to the 
developer and/or investor;
•	 Maintaining communications between technology developer 
and investor;
•	 Assisting in negotiations and/or deal structure;
•	 Identifying commercial opportunities for a technology.
The first three roles not only keep the deal moving but also help 
build the relationship between technology developer and investor; 
this is particularly important when the two parties will work together 
after deal signing. The last role, while not common, can nonetheless 
be critical as many technologies require other enabling technologies 
in order to be useful. In gene therapy, for example, a complete 
approach might include a particular cell line, a specific vector and 
corresponding gene vectors, each of which might be licensed from 
different developers. By virtue of their broader vision, broker is 
often able to put together these pieces when a single inventor cannot.
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Due Diligence Failures
Due diligence is the process by which an investor investigates 
a technology and its developer to determine whether or not a 
relationship is appropriate. Even in circumstances involving 
competitive bidding and/or time sensitivity, it is generally 
considered that the more thorough the due diligence process, the 
better, as this is the primary means by which a investor can fully 
evaluate a technology. Key factors to consider include, but are not 
limited to:
•	 Ability of the technology to perform as desired ;
•	 Demonstrated successes of the technology;
•	 Ability of the technology to perform consistently;
•	 Existence of other technology investors and their experiences 
with the technology and its developer;
•	 Patent issues;
•	 Ability of the technology to meet investor needs;
•	 Expertise within the investor organization to work with the 
technology;
•	 Resources within the developer organization to provide investor 
assistance;
•	 Financial and managerial strength of the developer organization;
•	 Any roadblocks to the ability of both organizations to work 
together.
Where shortfalls in any of these areas are found, they should 
be thoroughly vetted so that the investor has a clear understanding 
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of the strengths, weakness and potential pitfalls of the technology 
and relationship with its developer. This may involve not only many 
meetings between scientific and managerial personnel, but also a 
significant amount of background work to check the validity of the 
technology in the context of its prior usage and the investor’s own 
needs. While this can be time consuming, the rewards can be great, 
as thorough due diligence can prevent many serious downstream 
problems including overestimation of market value of technology; 
low commitment on the part of the technology developer to the 
relationship, incompatible objectives and selection of the wrong 
partner.
Unfortunately, many biotech tech transfer investors do not invest 
sufficient time or resources in this process to fully understand the 
scope of the technology and the relationship with its developer. 
Instead, much of the was spent discussing monetary terms and/or 
exclusivity while diligence requirements were much less rigorous.
Patent Issues
Patent issues are also critically important, since a lack of patent 
protection for technologies under development could instantly 
remove any gains from technology development. In this regard, the 
two items of most concern to a tech transfer investor are:
•	 Solid and comprehensive patent protection for any technologies 
or products already developed by the partner, which would be 
jointly used or developed;
•	 An agreement regarding ownership of any intellectual property 
arising from the development of additional technologies or 
products during the partnership.
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Most university have sufficient legal resources to address both 
of these issues. When working with university-based technologies, 
therefore, technology transfer investors can usually expect that 
patents have been issued or applied for; in cases of early stage and/
or quickly emerging technologies, legal resources are usually made 
available to address these issues once a investor indicates interest.
Start-up companies and other groups, however, often do not 
have easy access to patent attorneys and other legal expertise. 
In these cases, the investing company may have to verify the 
patentability of the invention on its own in order to ensure that the 
technology is, in fact, proprietary. This is also a necessary step in 
determining deal value, since a technology that is not proprietary 
– or infringes on another patent - cannot command the same price 
tag as a technology that is truly unique.
Deal Structure
The structure of a biotech tech transfer agreement typically involves 
several key terms including payments, exclusivity, termination 
clauses and responsibilities. This last item is particularly important 
where the developer and investor will have an ongoing relationship 
and in fact, the most successful biotech tech transfers tend to be 
those in which relationships between technology developers and 
investors are well defined from the outset. This includes a clear 
written agreement between the parties that delineates all items of 
interest such as compensation, intellectual property ownership, areas 
in which the investor may utilize the technology and/or exclusivity, 
ability of the investor to sub-license the technology, warranties and 
contingencies for termination. A well-written contract is particularly 
important when the arrangement will feature an ongoing working 
relationship between the parties. In this case, it should specifically 
include, in addition to the items above:
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•	 Pay and rewards linked to performance of the technology and/
or the developer;
•	 Early establishment of a small and consistent core team 
including key players at the developer and investor;
•	 Clear division of responsibilities between the technology 
developer and investor. Although the investor’s overarching 
R&D goals may be quite broad, including, for example, 
the introduction of new clinical candidates, additional drug 
approvals, etc., technology performance as determined via 
due diligence and defined by the contract is usually limited to 
certain very specific and well-defined objectives related to the 
unique capabilities of the technology itself.
It should also be noted that in many cases, the technology 
investor has considerably more input into the development of the 
contract and often writes the agreement. In these cases, the developer 
may feel compelled to accept terms that are not as favourable as it 
would like, leading to potential fulfilment discrepancies as project 
work starts. Ideally, both technology developer and investor should 
remain cognizant of these issues and develop an agreement that 
delineates attainable roles and responsibilities for both parties; 
however, this is not always the case, especially when an eager 
technology developer needs funding for ongoing operations. The 
less common exception to this is “hot” technologies with multiple 
suitors; in these cases, the developer may find that it has the upper 
hand in negotiations and may even benefit from bidding wars among 
competitors.
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Opportunities and Challenges in Emerging Markets
Healthcare opportunities include:
•	 Diversification opportunities outside of big biopharma markets 
(i.e.,. US, Europe and Japan)
•	 Access to large and varied populations;
•	 Access to worldwide talent and science;
•	 Economies of scale for return on investment;
•	 Increasing and earlier detection of diseases;
•	 High rates of infectious disease, “developing world” diseases, 
HIV/AIDS and hepatitis;
•	 Respiratory diseases due to high rates of smoking, pollution, 
and industrialization;
•	 Large pediatrics markets in countries with high birth rates;
•	 Increasing rates of chronic diseases including hypertension and 
diabetes with longer lifespans.
The opportunities presented by the emerging markets are 
numerous:
•	 Large populations;
•	 High unmet medical need;
•	 Population growth;
•	 Growing economies;
•	 Increasing public and private healthcare expenditures;
•	 Increasing philanthropic funds;
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•	 Lower labour costs;
The challenges presented by the emerging markets are also 
numerous and include:
•	 Diversity of languages and cultures;
•	 Patent law/intellectual property protection;
•	 Diverse healthcare structures and policy;
•	 Distribution logistics;
•	 Talent pool/education/literacy rates;
•	 Political environment and stability;
•	 Country or healthcare infrastructure;
•	 Foreign exchange risk;
•	 Security issues;
•	 Complexity of Human Resource and labor issues;
•	 Pricing regulations and controls;
•	 Local regulations, taxes and tariffs, and
•	 Preferential treatment for domestic companies.
Value Creation Via Merger & Acquisition (M&A)
M&A deals among biopharmaceutical companies are likely to 
gain in popularity as more companies look to generate growth 
from biological products. Expanding product portfolios and 
gaining access to technology will continue to be the main drivers 
of acquisitions. Biopharmaceutical companies are forecast to be 
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the most active acquirers of biopharmaceutical concerns, with 
inter-company deals accounting for a smaller but substantial 
share. Competition for late-stage candidates will shift the focus 
to earlier-stage product deals as biosimilars gain market approval. 
Biopharmaceutical companies that build their business through 
acquiring a broad product range and wide geographical market 
spread will be favourably positioned to attract new investment and 
future alliances. These companies will in turn be potential targets 
for big-league pharmaceutical companies.
Figure 17  M&A and leading pharmaceutical companies  
CONCLUSION
Efforts to develop therapeutic proteins, vaccines and other biologics 
that will change the lives of the many are, for human or animal 
use, getting more challenging, costly and risky. Certainly, the 
disease areas represent high unmet medical need and it has proved 
challenging to find effective therapies. Whilst the development of 
biopharmaceuticals provides a unique opportunity for successful 
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therapies in these areas, the technical hurdles to approval and 
launch a new product can be high.  The disease may not be 
well understood and the clinical pathways to approval are often 
untested. Technology transfer is becoming an important way for 
biopharmaceutical developers to access new approaches to increase 
R&D productivity and output. Meanwhile, expectations for new 
drugs from regulatory agencies, from patients and from payers 
are getting higher.  Regulatory agencies are rightly focused on 
patient safety and risk management more than ever before.  It is not 
enough to demonstrate that a medicine is safe and effective – drug 
developers must also demonstrate that it adds value to payers and 
is a significant improvement upon existing therapies.  This means 
that the time to develop new medicines is getting longer and costs 
are increasing.   There will also be increasing pressure on pricing 
and cost of goods as biologics progress into therapy areas where 
much cheaper medicines are already available. So what will make 
biopharmaceutical and biotech companies successful in developing 
new medicines over the next decade?  Certainly, scientific and 
operational excellence coupled with a global focus will be the key. 
Re-structuring to ensure optimal use of resources and to ensure 
nimble decision-making is occurring across the industry.  Most 
biopharmaceutical companies are looking to optimize their 
processes to reduce cycle time and increase the probability of 
success.  However, it is ultimately right human resource that 
will make the difference.  Outstanding leadership, recruiting and 
retaining key talent and fostering an environment that allows 
creativity and managed risk-taking to flourish will distinguish the 
new biopharmaceutical and biotech giants, and that is the way 
forwards to address the issue on twists and turns post-genomic area.
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BIOGRAPHY
Mohd Azmi Mohd Lila, aged 46, since 1990 and currently is 
with Department of Pathology and Microbiology, Faculty of 
Veterinary Medicine, Universiti Putra Malaysia. He has many 
years of experience serving various aspects of life sciences and 
biotechnology especially in research and development (R&D), 
product and technology innovations, technology acquisitions 
and investments, entrepreneurship, commercialisation of IPs and 
technology management. He has been engaged as a consultant and 
advisor by many companies and served as a committee member 
of various private and government institutions and authorities 
including Khazanah Nasional Berhad, Ministry of Human Resource 
for recruitment of human resource for emerging industry in 
Malaysia, committee member of Self-reliance Vaccine Production 
Program (by Islamic Development Bank, OIC), and Malaysian Debt 
Venture for setting up of RM1.4 billion debt venture fund.
He was also the chief executive officer and executive director 
of Ninebio Sdn Bhd (2009-2011), a government owned company 
(GLC) focused in research and development, commercialisation, 
manufacturing and distribution of vaccines, biologics and 
natural products. Ninebio provides supporting services related to 
manufacturing and HALAL certification activities to multinational 
companies to include Merck, GlaxoSmithKine and Novartis. He 
was responsible for the strategic direction, business development 
and overall management of the company. Throughout his tenure, 
he managed to restructure the company to ensure the right business 
direction, right funding requirement, financing and to ensure good 
governance/compliance in place.
Prior the secondment to Ninebio, he was the Director & 
Head of Investment at the Malaysian Technological Development 
Corporation (MTDC) (2006-2008), a Government owned venture 
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capital company and also handling government grant funding 
aiming to spearhead commercialisation and the development of 
technology-driven businesses in Malaysia. During his tenure there, 
he was responsible in managing the investment portfolio of few 
hundred million ringgits. His key areas of responsibilities include 
deal sourcing, evaluation of companies and business proposals, 
monitoring of investment and investee companies as well as 
corporate finance activities including deal structuring, management 
buy-outs (MBO) and fund raising. Throughout the process, he has 
reviewed extensive numbers of business plans and visited hundreds 
of business establishment for investment decision purposes. 
Dr. Mohd Azmi served as a BOD member of various investee 
companies in Malaysian abroad; and some of these companies are 
now on the path towards public listing.  He was also responsible 
for the establishment of Malaysian Life Science Capital Fund, 
USD150million, a joint venture company Malaysia-USA) and also 
as a member of Investment Committee. The nature of business of 
investee companies under him ranging from R&D to manufacturing 
of life sciences products, vaccines and pharmaceuticals, healthcare 
products, fertilizers, minerals, chemicals, waste management & 
recycling, bio-diesel and bio-fuel (upstream development and 
engineering), biomedical devices/equipment, electronics, energy 
conservation and carbon-credit (CDM) related companies. Dr Mohd 
Azmi was also an exco member and the Honorary Secretary of 
Malaysian Venture Capital Association (MVCA). MVCA oversees 
programs and activities of venture capital and private equity 
investment companies in Malaysia. 
He used to serve as a Director to public listed companies 
including TDM Berhad (plantation & healthcare sectors) and INS 
Bioscience Berhad (natural products & marketing).
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He was the Director of the University Business Centre (2001-
2002) and the Director of Institute of Bioscience (2004-2006). He 
has contributed and collaborated with many researchers in various 
research works and had his works published in various journals and 
publications (more than 250 publications). He managed to secure 
large amount of research funding from the government and private 
sector for R&D and acquisition of technology. He has supervised 
about 50 post postgraduates and at least 35 of them have graduated 
with MSc and/or PhD. He has numbers patented/patent pending 
invention and won many  awards/international recognitions for 
his research and achievements, and to name a few: Geneva gold 
award, MAMPU innovation award, The Outstanding Young Malaysia 
Award, UMNO Melayu Cemerlang Award, PESAT (Terengganu) 
Award, and Outstanding Research Award (UPM). 
Dr Mohd Azmi was born in 1964 in Chabang Tiga (Kuala 
Terengganu); primary school Sekolah Rendah Kebangsaan Pusat 
Chabang Tiga (1971-76); secondary school Sekolah Menengah 
Sultan Ahmad, Kuala Terengganu (1977-1981), received his first 
degree DVM from the Universiti Putra Malaysia (UPM, 1983/88) 
and PhD in Virology/Immunology from the University of Cambridge 
(UK) (1991/1994). He also holds MBA in Finance/Marketing from 
the UPM (1996/2000) and Masters of Law (Business Law) from 
the International Islamic University Malaysia (IIUM) (2006/2007).
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 The Challenge to Communication Research in Extension
 22 July 1989
2.  Prof. Ir. Abang Abdullah Abang Ali
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 30 August 1990
3.  Prof. Dr. Abdul Rahman Abdul Razak
 Plant Parasitic Nematodes, Lesser Known Pests of Agricultural Crops
 30 January 1993
4.  Prof. Dr. Mohamed Suleiman
 Numerical Solution of Ordinary Differential Equations: A Historical 
Perspective
 11 December 1993
5.  Prof. Dr. Mohd. Ariff Hussein
 Changing Roles of Agricultural Economics
 5 March 1994
6.  Prof. Dr. Mohd. Ismail Ahmad
 Marketing Management: Prospects and Challenges for Agriculture
 6 April 1994
7.  Prof. Dr. Mohamed Mahyuddin Mohd. Dahan
 The Changing Demand for Livestock Products
 20 April 1994
8.  Prof. Dr. Ruth Kiew
 Plant Taxonomy, Biodiversity and Conservation
 11 May 1994
9.  Prof. Ir. Dr. Mohd. Zohadie Bardaie
 Engineering Technological Developments Propelling Agriculture into the 
21st Century
 28 May 1994
10.  Prof. Dr. Shamsuddin Jusop
 Rock, Mineral and Soil
 18 June 1994
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11.  Prof. Dr. Abdul Salam Abdullah
 Natural Toxicants Affecting Animal Health and Production
 29 June 1994
12.  Prof. Dr. Mohd. Yusof Hussein
 Pest Control: A Challenge in Applied Ecology
 9 July 1994
13.  Prof. Dr. Kapt. Mohd. Ibrahim Haji Mohamed
 Managing Challenges in Fisheries Development through Science and   
Technology
 23 July 1994
14.  Prof. Dr. Hj. Amat Juhari Moain
 Sejarah Keagungan Bahasa Melayu
 6 Ogos 1994
15. Prof. Dr. Law Ah Theem
 Oil Pollution in the Malaysian Seas
 24 September 1994
16.  Prof. Dr. Md. Nordin Hj. Lajis
 Fine Chemicals from Biological Resources: The Wealth from Nature
 21 January 1995
17.  Prof. Dr. Sheikh Omar Abdul Rahman
 Health, Disease and Death in Creatures Great and Small
 25 February 1995
18.  Prof. Dr. Mohamed Shariff Mohamed Din
 Fish Health: An Odyssey through the Asia - Pacific Region
 25 March 1995
19.  Prof. Dr. Tengku Azmi Tengku Ibrahim
 Chromosome Distribution and Production Performance of Water Buffaloes
 6 May 1995
20.  Prof. Dr. Abdul Hamid Mahmood
 Bahasa Melayu sebagai Bahasa Ilmu- Cabaran dan Harapan
 10 Jun 1995
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21.  Prof. Dr. Rahim Md. Sail
 Extension Education for Industrialising Malaysia: Trends, Priorities and  
Emerging Issues
 22 July 1995
22.  Prof. Dr. Nik Muhammad Nik Abd. Majid
 The Diminishing Tropical Rain Forest: Causes, Symptoms and Cure
 19 August 1995
23.  Prof. Dr. Ang Kok Jee
 The Evolution of an Environmentally Friendly Hatchery Technology for 
Udang Galah, the King of Freshwater Prawns and a Glimpse into the 
Future of Aquaculture in the 21st Century
 14 October 1995
24.  Prof. Dr. Sharifuddin Haji Abdul Hamid
 Management of Highly Weathered Acid Soils for Sustainable Crop 
Production
 28 October 1995 
25.  Prof. Dr. Yu Swee Yean
 Fish Processing and Preservation: Recent Advances and Future Directions
 9 December 1995
26.  Prof. Dr. Rosli Mohamad
 Pesticide Usage: Concern and Options
 10 February 1996
27.  Prof. Dr. Mohamed Ismail Abdul Karim
 Microbial Fermentation and Utilization of Agricultural Bioresources and 
Wastes in Malaysia
 2 March 1996
28.  Prof. Dr. Wan Sulaiman Wan Harun
 Soil Physics: From Glass Beads to Precision Agriculture
 16 March 1996
29.  Prof. Dr. Abdul Aziz Abdul Rahman
 Sustained Growth and Sustainable Development: Is there a Trade-Off 1 or 
Malaysia
 13 April 1996
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30.  Prof. Dr. Chew Tek Ann
 Sharecropping in Perfectly Competitive Markets: A Contradiction in Terms
 27 April 1996
31.  Prof. Dr. Mohd. Yusuf Sulaiman
 Back to the Future with the Sun
 18 May 1996
32.  Prof. Dr. Abu Bakar Salleh
 Enzyme Technology: The Basis for Biotechnological Development
 8 June 1996
33.  Prof. Dr. Kamel Ariffin Mohd. Atan
 The Fascinating Numbers
 29 June 1996
34.  Prof. Dr. Ho Yin Wan
 Fungi: Friends or Foes
 27 July 1996
35.  Prof. Dr. Tan Soon Guan
 Genetic Diversity of Some Southeast Asian Animals: Of Buffaloes and 
Goats and Fishes Too
 10 August 1996
  
36.  Prof. Dr. Nazaruddin Mohd. Jali
 Will Rural Sociology Remain Relevant in the 21st Century?
 21 September 1996
37.  Prof. Dr. Abdul Rani Bahaman
 Leptospirosis-A Model for Epidemiology, Diagnosis and Control of 
Infectious Diseases
 16 November 1996
38.  Prof. Dr. Marziah Mahmood
 Plant Biotechnology - Strategies for Commercialization
 21 December 1996
39.  Prof. Dr. Ishak Hj. Omar
 Market Relationships in the Malaysian Fish Trade: Theory and Application
 22 March 1997
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40.  Prof. Dr. Suhaila Mohamad
 Food and Its Healing Power
 12 April 1997
41.  Prof. Dr. Malay Raj Mukerjee
 A Distributed Collaborative Environment for Distance Learning 
Applications
 17 June 1998
42.  Prof. Dr. Wong Kai Choo
 Advancing the Fruit Industry in Malaysia: A Need to Shift Research 
Emphasis
 15 May 1999
43.  Prof. Dr. Aini Ideris
 Avian Respiratory and Immunosuppressive Diseases- A Fatal Attraction
 10 July 1999
44.  Prof. Dr. Sariah Meon
 Biological Control of Plant Pathogens: Harnessing the Richness of 
Microbial Diversity
 14 August 1999
45.  Prof. Dr. Azizah Hashim
 The Endomycorrhiza: A Futile Investment?
 23 Oktober 1999
46.  Prof. Dr. Noraini Abdul Samad
 Molecular Plant Virology: The Way Forward
 2 February 2000
47.  Prof. Dr. Muhamad Awang
 Do We Have Enough Clean Air to Breathe?
 7 April 2000
48.  Prof. Dr. Lee Chnoong Kheng
 Green Environment, Clean Power
 24 June 2000
49.  Prof. Dr. Mohd. Ghazali Mohayidin
 Managing Change in the Agriculture Sector: The Need for Innovative 
Educational Initiatives
 12 January 2002
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50.  Prof. Dr. Fatimah Mohd. Arshad
 Analisis Pemasaran Pertanian di Malaysia: Keperluan Agenda 
Pembaharuan
 26 Januari 2002
51.  Prof. Dr. Nik Mustapha R. Abdullah
 Fisheries Co-Management: An Institutional Innovation Towards 
Sustainable Fisheries Industry
 28 February 2002
52.  Prof. Dr. Gulam Rusul Rahmat Ali
 Food Safety: Perspectives and Challenges
 23 March 2002
53.  Prof. Dr. Zaharah A. Rahman
 Nutrient Management Strategies for Sustainable Crop Production in Acid 
Soils: The Role of Research Using Isotopes
 13 April 2002
54.  Prof. Dr. Maisom Abdullah
 Productivity Driven Growth: Problems & Possibilities
 27 April 2002
55.  Prof. Dr. Wan Omar Abdullah
 Immunodiagnosis and Vaccination for Brugian Filariasis: Direct Rewards 
from Research Investments
 6 June 2002
56.  Prof. Dr. Syed Tajuddin Syed Hassan
 Agro-ento Bioinformation: Towards the Edge of Reality
 22 June 2002
57.  Prof. Dr. Dahlan Ismail
 Sustainability of Tropical Animal-Agricultural Production Systems: 
Integration of Dynamic Complex Systems
 27 June 2002
58.  Prof. Dr. Ahmad Zubaidi Baharumshah
 The Economics of Exchange Rates in the East Asian Countries
 26 October 2002
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59.  Prof. Dr. Shaik Md. Noor Alam S.M. Hussain
 Contractual Justice in Asean: A Comparative View of Coercion
 31 October 2002
60.  Prof. Dr. Wan Md. Zin Wan Yunus
 Chemical Modification of Polymers: Current and Future Routes for 
Synthesizing New Polymeric Compounds
 9 November 2002
61.  Prof. Dr. Annuar Md. Nassir
 Is the KLSE Efficient? Efficient Market Hypothesis vs Behavioural Finance
 23 November 2002
62.  Prof. Ir. Dr. Radin Umar Radin Sohadi
 Road Safety Interventions in Malaysia: How Effective Are They?
 21 February 2003
63.  Prof. Dr. Shamsher Mohamad
 The New Shares Market: Regulatory Intervention, Forecast Errors and 
Challenges
 26 April 2003
64.  Prof. Dr. Han Chun Kwong
 Blueprint for Transformation or Business as Usual? A Structurational 
Perspective of the Knowledge-Based Economy in Malaysia
 31 May 2003
65.  Prof. Dr. Mawardi Rahmani
 Chemical Diversity of Malaysian Flora: Potential Source of Rich 
Therapeutic Chemicals
 26 July 2003
66.  Prof. Dr. Fatimah Md. Yusoff
 An Ecological Approach: A Viable Option for Aquaculture Industry in 
Malaysia
 9 August 2003
67.  Prof. Dr. Mohamed Ali Rajion
 The Essential Fatty Acids-Revisited
 23 August 2003
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68.  Prof. Dr. Azhar Md. Zain
 Psychotheraphy for Rural Malays - Does it Work?
 13 September 2003
69.  Prof. Dr. Mohd. Zamri Saad
 Respiratory Tract Infection: Establishment and Control
 27 September 2003
70.  Prof. Dr. Jinap Selamat
 Cocoa-Wonders for Chocolate Lovers
 14 February 2004
71.  Prof. Dr. Abdul Halim Shaari
 High Temperature Superconductivity: Puzzle & Promises
 13 March 2004
72.  Prof. Dr. Yaakob Che Man
 Oils and Fats Analysis - Recent Advances and Future Prospects
 27 March 2004
73.  Prof. Dr. Kaida Khalid
 Microwave Aquametry: A Growing Technology
 24 April 2004
74.  Prof. Dr. Hasanah Mohd. Ghazali
 Tapping the Power of Enzymes- Greening the Food Industry
 11 May 2004
75.  Prof. Dr. Yusof Ibrahim
 The Spider Mite Saga: Quest for Biorational Management Strategies
 22 May 2004
76.  Prof. Datin Dr. Sharifah Md. Nor
 The Education of At-Risk Children: The Challenges Ahead
 26 June 2004
77.  Prof. Dr. Ir. Wan Ishak Wan Ismail
 Agricultural Robot: A New Technology Development for Agro-Based 
Industry
 14 August 2004
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78.  Prof. Dr. Ahmad Said Sajap
 Insect Diseases: Resources for Biopesticide Development
 28 August 2004
79.  Prof. Dr. Aminah Ahmad
 The Interface of Work and Family Roles: A Quest for Balanced Lives
 11 March 2005
80.  Prof. Dr. Abdul Razak Alimon
 Challenges in Feeding Livestock: From Wastes to Feed
 23 April 2005
81.  Prof. Dr. Haji Azimi Hj. Hamzah
 Helping Malaysian Youth Move Forward: Unleashing the Prime Enablers
 29 April 2005
82.  Prof. Dr. Rasedee Abdullah
 In Search of An Early Indicator of Kidney Disease
 27 May 2005
83.  Prof. Dr. Zulkifli Hj. Shamsuddin
 Smart Partnership: Plant-Rhizobacteria Associations
 17 June 2005
84.  Prof. Dr. Mohd Khanif Yusop
 From the Soil to the Table
 1 July 2005
85.  Prof. Dr. Annuar Kassim
 Materials Science and Technology: Past, Present and the Future
 8 July 2005
86.  Prof. Dr. Othman Mohamed
 Enhancing Career Development Counselling and the Beauty of Career 
Games
 12 August 2005
87.  Prof. Ir. Dr. Mohd Amin Mohd Soom
 Engineering Agricultural Water Management Towards Precision Framing
 26 August 2005
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88.  Prof. Dr. Mohd Arif Syed
 Bioremediation-A Hope Yet for the Environment?
 9 September 2005
89.  Prof.  Dr. Abdul Hamid Abdul Rashid
 The Wonder of Our Neuromotor System and the Technological Challenges 
They Pose
 23 December 2005
90.  Prof. Dr. Norhani Abdullah
 Rumen Microbes and Some of Their Biotechnological Applications
 27 January 2006
91.  Prof. Dr. Abdul Aziz Saharee
 Haemorrhagic Septicaemia in Cattle and Buffaloes: Are We Ready for 
Freedom?
 24 February 2006
92.  Prof. Dr. Kamariah Abu Bakar
 Activating Teachers’ Knowledge and Lifelong Journey in Their Profes-
sional Development
 3 March 2006
93.  Prof. Dr. Borhanuddin Mohd. Ali
 Internet Unwired
 24 March 2006
94.  Prof. Dr. Sundararajan Thilagar
 Development and Innovation in the Fracture Management of Animals
 31 March 2006
95.  Prof. Dr. Zainal Aznam Md. Jelan
 Strategic Feeding for a Sustainable Ruminant Farming
 19 May 2006
96.  Prof. Dr. Mahiran Basri
 Green Organic Chemistry: Enzyme at Work
 14 July 2006
97.  Prof. Dr. Malik Hj. Abu Hassan
 Towards Large Scale Unconstrained Optimization
 20 April 2007
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98. Prof. Dr. Khalid Abdul Rahim
 Trade and  Sustainable Development: Lessons from Malaysia’s Experience
 22 Jun 2007
99. Prof. Dr. Mad Nasir Shamsudin
 Econometric Modelling for Agricultural Policy Analysis and Forecasting:  
Between Theory and Reality
 13 July 2007
100. Prof. Dr. Zainal Abidin Mohamed
 Managing Change - The Fads and The Realities:  A Look at Process 
Reengineering, Knowledge Management and Blue Ocean Strategy 
 9 November 2007
101. Prof. Ir. Dr. Mohamed Daud
 Expert Systems for Environmental Impacts and Ecotourism Assessments 
 23 November 2007
102. Prof. Dr. Saleha Abdul Aziz
 Pathogens and Residues;  How Safe is Our Meat?
 30 November 2007
103. Prof. Dr. Jayum A. Jawan
 Hubungan Sesama Manusia
 7 Disember 2007
104. Prof. Dr. Zakariah Abdul Rashid
 Planning for Equal Income Distribution in Malaysia:  A General 
Equilibrium Approach
 28 December 2007
105. Prof. Datin Paduka Dr. Khatijah Yusoff
 Newcastle Disease virus: A Journey from Poultry to Cancer
 11 January 2008
106. Prof. Dr. Dzulkefly Kuang Abdullah
 Palm Oil: Still the Best Choice
 1 February 2008
107. Prof. Dr. Elias Saion
 Probing the Microscopic Worlds by Lonizing Radiation
 22 February 2008
❚❘❘ 126
Biopharmaceutical: Protection, Cure and the Real Winner
108. Prof. Dr. Mohd Ali Hassan
 Waste-to-Wealth Through Biotechnology: For Profit, People and Planet
 28 March 2008
109. Prof. Dr. Mohd Maarof H. A. Moksin
 Metrology at Nanoscale: Thermal Wave Probe Made It Simple
 11 April 2008
110. Prof. Dr. Dzolkhifli Omar
 The Future of Pesticides Technology in Agriculture: Maximum Target Kill 
with Minimum Collateral Damage
 25 April 2008 
111. Prof. Dr. Mohd. Yazid Abd. Manap
 Probiotics: Your Friendly Gut Bacteria
 9 May 2008
112. Prof. Dr. Hamami Sahri
 Sustainable Supply of  Wood and Fibre: Does Malaysia have Enough?
 23 May 2008
113. Prof. Dato’ Dr. Makhdzir Mardan
 Connecting the Bee Dots
 20 June 2008
114. Prof. Dr. Maimunah Ismail
 Gender & Career: Realities and Challenges
 25 July 2008
115. Prof. Dr. Nor Aripin Shamaan
 Biochemistry of Xenobiotics: Towards a Healthy Lifestyle and Safe 
Environment
 1 August 2008
116. Prof. Dr. Mohd Yunus Abdullah
 Penjagaan Kesihatan Primer di Malaysia:  Cabaran Prospek dan 
Implikasi dalam Latihan dan Penyelidikan Perubatan serta Sains 
Kesihatan di Universiti Putra Malaysia
 8 Ogos 2008
117. Prof. Dr. Musa Abu Hassan
 Memanfaatkan Teknologi Maklumat & Komunikasi ICT untuk Semua
 15 Ogos 2008
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118. Prof. Dr. Md. Salleh Hj. Hassan
 Role of Media in Development:  Strategies, Issues & Challenges
 22 August 2008
119. Prof. Dr. Jariah Masud
 Gender in Everyday Life
 10 October 2008
120 Prof. Dr. Mohd Shahwahid Haji Othman
 Mainstreaming Environment: Incorporating Economic Valuation and 
Market-Based Instruments in Decision Making
 24 October 2008
121. Prof. Dr. Son Radu
 Big Questions Small Worlds: Following Diverse Vistas
 31 Oktober 2008
122. Prof. Dr. Russly Abdul Rahman
 Responding to Changing Lifestyles: Engineering the Convenience Foods 
28 November 2008
123. Prof. Dr. Mustafa Kamal Mohd Shariff
 Aesthetics in the Environment an Exploration of Environmental: 
Perception Through Landscape Preference
 9 January 2009
124. Prof. Dr. Abu Daud Silong
 Leadership Theories, Research & Practices:  Farming Future Leadership 
Thinking
 16 January 2009
125. Prof. Dr. Azni Idris
 Waste Management, What is the Choice: Land Disposal or Biofuel?
 23 January 2009
126. Prof. Dr. Jamilah Bakar
 Freshwater  Fish: The Overlooked Alternative
 30 January 2009
127. Prof. Dr. Mohd. Zobir Hussein
 The Chemistry of Nanomaterial and Nanobiomaterial
 6 February 2009
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128. Prof. Ir. Dr. Lee Teang Shui
 Engineering Agricultural: Water Resources
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129. Prof. Dr. Ghizan Saleh
 Crop Breeding: Exploiting Genes for Food and Feed
 6 March 2009
130. Prof. Dr. Muzafar Shah Habibullah
 Money Demand
 27 March 2009
131.  Prof. Dr. Karen Anne Crouse
 In Search of Small Active Molecules
 3 April 2009
132. Prof. Dr. Turiman Suandi
 Volunteerism: Expanding the Frontiers of Youth Development
 17 April 2009
133. Prof. Dr. Arbakariya Ariff
 Industrializing Biotechnology: Roles of Fermentation and Bioprocess 
Technology
 8 Mei 2009
134. Prof. Ir. Dr. Desa Ahmad
 Mechanics of Tillage Implements
 12 Jun 2009
135. Prof. Dr. W. Mahmood Mat Yunus
 Photothermal and Photoacoustic: From Basic Research to Industrial 
Applications
 10 Julai 2009
136. Prof. Dr. Taufiq Yap Yun Hin
 Catalysis for a Sustainable World
 7 August 2009
137 Prof. Dr. Raja Noor Zaliha Raja Abd. Rahman
  Microbial Enzymes: From Earth to Space
  9 Oktober 2009
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138 Prof. Ir. Dr. Barkawi Sahari 
 Materials, Energy and CNGDI Vehicle Engineering
 6 November 2009
139. Prof. Dr. Zulkifli Idrus
 Poultry Welfare in Modern Agriculture: Opportunity or Threat?
 13 November 2009
140. Prof. Dr. Mohamed Hanafi Musa
 Managing Phosphorus: Under Acid Soils Environment
 8 January 2010
141. Prof. Dr. Abdul Manan Mat Jais
 Haruan Channa striatus a Drug Discovery in an Agro-Industry Setting
 12 March 2010
142. Prof. Dr. Bujang bin Kim Huat
 Problematic Soils:  In Search for Solution
 19 March 2010
143. Prof. Dr. Samsinar Md Sidin
 Family Purchase Decision Making:  Current Issues & Future Challenges
 16 April 2010
144. Prof. Dr. Mohd Adzir Mahdi
 Lightspeed:  Catch Me If  You Can
 4 June 2010
145. Prof. Dr. Raha Hj. Abdul Rahim
 Designer Genes: Fashioning Mission Purposed Microbes
 18 June 2010
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